Growth factors for use in treating charcot-marie-tooth disease
Patent Information
- Application Number
- PCT/GB2024/050626
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-09
- Filing Date
- 2024-03-08
- Publication Date
- 2024-12-12
AI Technical Summary
Charcot-Marie-Tooth disease (CMT) lacks effective disease-modifying therapies, with patients experiencing muscle weakness and sensory deficits due to neuropathy affecting motor and sensory neurons, primarily caused by mutations in aminoacyl-tRNA synthetase (ARS) genes leading to impaired axonal transport and protein synthesis.
Administration of Brain-Derived Neurotrophic Factor (BDNF) and/or Glial Cell Line-Derived Neurotrophic Factor (GDNF) through direct injection or gene therapy to enhance neurotrophic signaling, specifically targeting muscles to correct axonal transport defects in CMT2D and DI-CMTC models by using self-complementary AAV vectors with muscle-specific promoters to ensure localized expression.
Intramuscular administration of BDNF or GDNF rescues axonal transport in CMT2D and DI-CMTC mice, demonstrating potential as a therapeutic strategy for Charcot-Marie-Tooth disease by improving neuronal survival pathways and protein synthesis.
Smart Images

Figure GB2024050626_12122024_PF_FP_ABST
Abstract
Description
[0001] Therapy for Charcot-Marie-Tooth disease
[0002] This invention relates to therapies for Charcot-Marie-Tooth disease (CMT) and other hereditary peripheral neuropathies in a subject and associated compositions, uses and methods of manufacture.
[0003] Charcot-Marie-Tooth disease (CMT) is an inherited peripheral nerve disorder resulting in life-long disability, with no available disease-modifying therapies. Patients usually present with muscle weakness and wasting, as well as sensory deficits, in the hands and feet, indicating that motor and sensory neurons with the longest axons are generally the most susceptible to neuropathy. CMT can be categorised into two principal subtypes depending on pathogenesis and clinical assessment of upper limb motor nerve conduction velocity (NCV) in the median or ulnar nerve: type 1 / demyelinating CMT (CMT1) is caused by loss of the myelinating Schwann cells that ensheath peripheral nerves leading to reduced NCV (<38 m / s), whereas type 2 / axonal CMT (CMT2) is caused by loss of peripheral axons and has little effect on NCV (>45 m / s). Some forms of genetic peripheral neuropathy display clinical features of CMT1 and CMT2, including intermediate NCVs (25-45 m / s), and are thus categorised as intermediate CMT.
[0004] Given that CMT is caused by mutations in more than 90 genes with diverse functions, a single unifying pathomechanism is unlikely; nevertheless, compromised axonal transport has been identified in many CMT subtypes and is hypothesised to be a major driver of axon and synaptic degeneration. The gene family linked to the most CMT subtypes encode aminoacyl-tRNA synthetase (ARS) enzymes, which charge specific amino acids to cognate tRNAs, thereby maintaining the fidelity of the genetic code. Seven ARS genes have so far been linked to CMT (AARS1, GARS1, HARS1, MARS1, SARS1, WARSI and YARS1). ARS-related CMTs are all dominantly inherited and display a similar clinical phenotype. Although many ARS mutations affect tRNA aminoacylation, this is not a pre-requisite for disease. Rather, a toxic gain-of-function appears to be the primary driver of neuropathology.
[0005] CMT type 2D (CMT2D) usually manifests during adolescence due to dominantly inherited, missense mutations in the widely and constitutively expressed GARS1 gene, which encodes glycyl-tRNA synthetase (GlyRS), an enzyme essential for protein translation. Whereas the mechanisms causing selective motor and sensory nerve pathology in CMT2D remain to be fully resolved, GARS1 mutations have been reported to induce a conformational opening in GlyRS, exposing buried consensus surfaces that enable toxic mis-interactions with several proteins both inside and outside of neurons. Aberrant binding partners include the neuronal and vascular transmembrane receptor protein neuropilin-1 and the histone deacetylase HDAC6. Additional enhanced associations with wild-type GlyRS interactors are also possible. Indeed, recent evidence indicates that mutant GlyRS binds, but fails to efficiently release, tRNAGlyleading to ribosome stalling at glycine codons, inhibition of protein synthesis and activation of the integrated stress response. Accordingly, tRNAGlyoverexpression resulted in a rescue of neuropathy phenotypes in both Drosophila melanogaster and mouse models of CMT2D. Impaired protein translation is thus a major component of GARS1 neuropathy, as well as other diseases affecting peripheral nerves; however, the driver of differential vulnerability in neuropathy across motor and sensory neuron subtypes remains to be determined.
[0006] It was recently discovered that CMT2D-causing, but not wild-type, GlyRS interacts with extracellular domains of tropomyosin receptor kinase (Trk) receptors A, B and C, contributing to the developmental perturbation of sensory neurons in mutant Gars mice. Via their role as neurotrophin receptors, the Trk receptors are critical to neuronal differentiation and homeostasis. Through selective binding and internalisation of secreted neurotrophins at axon terminals, Trk receptors are retrogradely transported within signalling endosomes to somas, where they elicit gene transcription events essential for neuronal survival. TrkA preferentially binds to nerve growth factor (NGF), TrkB to both brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), and TrkC to neurotrophin-3 (NT- 3).
[0007] Heterozygous point mutations in tyrosyl-tRNA synthetase (TyrRS)-encoding YARS1 cause demyelinating and axonal neuropathy symptoms resulting in a diagnosis of dominant intermediate CMT type C (DI-CMTC). Patients display mild to moderate disease severity with intermediate NCVs and predominant motor versus sensory involvement. Similar to GlyRS, several different CMT mutations in YARS1 have been shown to cause mutant TyrRS to adopt an alternative stable conformation, which enhances its binding affinity for transcriptional regulators, TRIM28 and HDAC1. Moreover, a Drosophila melanogaster model of DI-CMTC, in which mutant YARS1 is overexpressed, displays a similar pattern of neuropathology and protein translation impairment in motor and sensory neurons to that caused by mutant GARS1. It therefore appears that GARS1- and KARSl-related neuropathies share several key features, suggesting that a common gain-of-function mechanism or mechanisms may mediate neuropathology linked to mutations in the ARS-encoding genes. Further supporting this hypothesis, structural relaxation and conformational opening are also caused by CMT mutations in alanyl-tRNA synthetase (AARS1) and histidyl-tRN A synthetase (HARS1). What is required is an effective treatment for Charcot-Marie-Tooth disease.
[0008] According to a first aspect of the present invention, there is provided BDNF and / or GDNF (glial cell line-derived neurotrophic factor) for use in the treatment or prevention of Charcot-Marie-Tooth disease (CMT) or other hereditary peripheral neuropathies, in a subject.
[0009] Advantageously, it has been found that targeting muscles with BDNF- or GDNF-boosting therapies could represent a viable therapeutic strategy for CMT2D, DI-CMTC and other ARS-related CMTs, as similar mechanisms of secretion and structural relaxation occur. In particular, it is herein conclusively demonstrated that altered neurotrophic signalling is integral to the CMT2D pathomechanism. Secreted by distal target cells, neurotrophins are long-distance signalling molecules taken-up by nerve termini and transported within signalling endosomes towards cell bodies - a process essential for neuronal survival called axonal transport. Through imaging of this process in live, anaesthetised mice, via a pioneering technique, it has been shown that CMT2D mice (GarsAETAQ / +) display impaired axonal transport of neurotrophin-containing signalling endosomes in vivo (Figure 1, B-C), a pathological feature found in other neurodegenerative diseases. Moreover, intramuscular injection of recombinant human CMT2D-causing GlyRS into the muscles of wild-type mice caused significant endosome transport impairment in otherwise healthy motor axons (Figure 1, D-G), consistent with a non-cell autonomous disease mechanism for CMT2D. Importantly, it has been confirmed that impairments in BDNF-TrkB signalling underlie CMT2D and that pharmacological disruption of the BDNF-TrkB pathway results in endosome transport defects in wild-type mice (Figure 5). Testing the hypothesis that the mis-interaction between mutant GlyRS and Trk receptors may be driving this transport impairment, recombinant BDNF was injected into CMT2D muscles. BDNF is the neurotrophin ligand for TrkB, the main Trk receptor at the neuromuscular junction (NMJ). This rescued the in vivo transport defects of GarsAETAC1 / +mice (Figure 7A). The data herein further confirms the relevance of the treatment strategy in another ARS-related neuropathy, which is dominant-intermediate CMT type C (DI-CMT). This is caused by mutations in TyrRS-encoding YARS1. It is shown that homozygous YarsE196Kmice display in vivo axonal transport defects (Figure 3) and that there is aberrant interaction between TyrRSE196Kand the extracellular domain of TrkB (Figure 4). The axonal transport is corrected with intramuscular injection of BDNF (Figure 7B).
[0010] Based on this work, novel self-complementary AAV (scAAV) were generated to selectively augment BDNF in muscles using either the muscle-specific tMCK or MHCK7 promoters, thus bypassing side effects caused by BDNF overexpression in the central nervous system. Intraperitoneal injections of AAV8-tMCK-eGFP at postnatal day 2 (P2) confirmed that BDNF was increased in a muscle-restricted fashion (Figure 9). We then tested intramuscular injections of the gene therapy vectors in 1 month- old GarsAETAa / +mice and 8 month-old YarsE196l< / E196l<mice. One month post-administration, boosting muscle BDNF levels successfully corrects axonal transport of signalling endosomes in the CMT2D (Figure 10) and DI-CMTC mice (Figure 11), compared with eGFP control virus. Altogether, these findings demonstrate that selectively increasing BDNF availability in CMT2D and DI-CMTC muscle corrects axonal transport defects. Therefore, this novel gene therapy approach is likely beneficial for the treatment of the human neuropathy. Downstream pro-survival pathways are shared between BDNF and GDNF. Advantageously, it has been demonstrated herein that intramuscular administration of BDNF or GDNF rescues GarsAETAC1 / +endosome in vivo transport to physiological levels (Figure 8), which demonstrates a role for the use of GDNF as well as BDNF. Moreover, a month-long treatment of GarsAETAa / +mice with AAV8-MHCK7-GDNF confirmed that increasing muscle-restricted expression of GDNF is also able to rescue in vivo axonal transport of signalling endosomes (Figure 12).
[0011] BDNF / GDNF Delivery
[0012] The skilled person will recognise that the treatment or prevention of CMT requires the provision of additional BDNF and / or GDNF at the site of the peripheral nerve axon terminal, for example in muscle tissue. The BDNF and / or GDNF can be delivered directly to a muscle of the subject, for example by injection of BDNF and / or GDNF into the muscle. Alternatively, gene therapy may be used to increase the expression ( / .e., overexpression) of endogenous or heterologous BDNF and / or GDNF in a local tissue site, such as muscle.
[0013] In a preferred embodiment, the provision of additional BDNF and / or GDNF (through direct injection or overexpression) is localised, and not systemic throughout the body of the subject. For example, BDNF and / or GDNF levels may not be increased in the central nervous system (CNS).
[0014] In one embodiment, the BDNF and / or GDNF is encoded in a nucleic acid for expression. In particular, the nucleic acid may be used to express BDNF and / or GDNF in the subject, preferably at a localised site, such as in muscle tissue. The nucleic acid may be DNA. The nucleic acid may be isolated, such as isolated DNA. The nucleic acid may be a vector, such as a viral vector. The expression of the BDNF and / or GDNF may be controlled by a promoter. The expression of BDNF and / or GDNF may be targeted to specific cells or tissues, for example by use of a cell- or tissue-specific promoter to control the expression of BDNF and / or GDNF. Additionally or alternatively, the nucleic acid may be specifically delivered to a targeted cell type or tissue, such as muscle.
[0015] In one embodiment, the BDNF and / or GDNF is encoded in a nucleic acid, which comprises a promoter sequence. In a preferred embodiment, the promoter is tissue- or cell-specific. In one embodiment, the promoter is muscle-specific. The promoter may not function in the cells of the central nervous system.
[0016] The skilled person may use any muscle-specific promoter, such as those identified by Skopenkova et al. (Acta Naturae 13: 47-58 (2021) https: / / doi.org / 10.32607 / actanaturae.11063), which is herein incorporated by reference. In one embodiment, the promoter comprises or consists of a muscle creatine kinase (MCK) promoter. The muscle-specific promoter may comprise or consist of any of the promoters selected from CK6, MHCK7, dMCK, tMCK, CK8, CK8e, desmin, C5-12, alpha-actin, HSA, HSA / CMV. In one embodiment, the muscle-specific promoter may comprise or consist of any of tMCK, MHCK7 and desmin.
[0017] In a preferred embodiment, the promoter comprises or consists of tMCK or MHCK7. In one embodiment, the promoter comprises or consists of the sequence of SEQ ID NO: 1 or 2, or a functional variant thereof. The skilled person will recognise that a functional variant of the promoter may have substantially the same specificity for expression in muscle tissue and for example could vary by addition, deletion, or substitution of one or more nucleotides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides. The variant sequence may have at least 80% sequence identity with SEQ ID NO: 1 or 2, or any other known muscle-specific promoter, such as those identified herein. In another embodiment, the variant sequence may have at least 90% sequence identity with SEQ. ID NO: 1 or 2, or any other known muscle-specific promoter, such as those identified herein. In another embodiment, the variant sequence may have at least 95% sequence identity with SEQ ID NO: 1 or 2, or any other known musclespecific promoter, such as those identified herein. In another embodiment, the variant sequence may have at least 98% sequence identity with SEQ ID NO: 1 or 2, or any other known muscle-specific promoter, such as those identified herein.
[0018] The skilled person will recognise that the promoter must be capable of promoting the gene(s) of interest, such as the gene(s) encoding BDNF and / or GDNF. The skilled person may construct the promoter and gene(s) appropriately, such that the promoter has the correct distancing and orientation for operably driving the expression of the gene(s) encoding BDNF and / or GDNF. The promoter may be positioned 5' to the sequence encoding the BDNF and / or GDNF.
[0019] Advantageously, the provision of gene therapy, allows for targeted delivery and expression of the BDNF and / or GDNF without side effects, for example in the CNS. Gene therapy can also ensure longer lasting effects relative to direct local administration of the protein.
[0020] The viral vector for nucleic acid expression of BDNF and / or GDNF may be any suitable viral vector that can be used to deliver genetic material to the cells of interest for expression of the BDNF and / or GDNF. Preferably, the viral vector can form non-replicating episomes for expression of BDNF and / or GDNF. In one embodiment, the viral vector is adeno-associated virus (AAV) vector. The AAV may be a self- complementary AAV (scAAV).
[0021] Advantageously, AAV is a virus that is not known to result in human disease and it cannot replicate in the body without further assistance. This allows safe and precise control of dosing. scAAV allows more efficient infection and can increase and prolong transgene expression, as well as providing a higher in vivo DNA stability and more effective circularization.
[0022] The viral vector for expression of GDNF may comprise or consist of the sequence of SEQ ID NO: 11. The AAV vector of SEQ. ID NO: 11 may be modified with the insertion of alternative gene sequences for BDNF and / or GDNF, and optionally an alternative promoter sequence, such as a muscle-specific sequence. The viral vector for expression of GDNF may comprise or consist of the sequence of SEQ ID NO: 11, which is further modified to substitute the MHCK7 promoter sequence with an alternative promoter sequence, preferably a muscle-specific promoter sequence, such as tMCK.
[0023] The viral vector for expression of BDNF may comprise or consist of the sequence of SEQ ID NO: 11, which is further modified to substitute the hGDNF-encoding sequence with a BDNF-encoding sequence. The viral vector for expression of BDNF may comprise or consist of the sequence of SEQ ID NO: 11, which is further modified to substitute the hGDNF-encoding sequence with a BDNF-encoding sequence and further modified to substitute the MHCK7 promoter sequence with an alternative promoter sequence, preferably a muscle-specific promoter sequence, such as tMCK. The viral vector may be packaged into a viral particle. The AAV plasmids may be packaged into AAV, such as AAV serotype 8. Other serotypes such as AAV9, AAV1 and rAAVrh74 may be used as an alternative.
[0024] The skilled person will recognise that AAVMYO capsid has been shown to provide strong muscle expression by Weinmann et al. (Nat Commun 11: 5432 (2020) https: / / doi.org / 10.1038 / s41467-020- 19230-w), which is herein incorporated by reference. The skilled person will further recognise that MyoAAV capsid sequence and plasmid have been shown to provide strong muscle expression using a MHCK7-GFP plasmid by Tabebordbar et al. (Cell 184: 4919-4938.e22 (2021) https: / / doi.Org / 10.1016 / j.cell.2021.08.028), which is herein incorporated by reference. AAVMYO or MyoAAV capsid may be used to deliver the nucleic acid and express BDNF and / or GDNF.
[0025] Gene Therapy Administration of nucleic acid encoding BDNF and / or GDNF
[0026] The administration of the nucleic acid encoding BDNF and / or GDNF, such as a viral vector, or a viral particle comprising the nucleic acid, may be by local administration to a nerve or muscle tissue. In another embodiment, the administration of the nucleic acid encoding BDNF and / or GDNF, or a viral particle comprising the nucleic acid, may be systemic, such as intravenous administration. In another embodiment, the nucleic acid encoding BDNF and / or GDNF, or a viral particle comprising the nucleic acid, may be administered subcutaneously.
[0027] The nucleic acid encoding BDNF and / or GDNF, or a viral particle comprising the nucleic acid, may be formulated in a composition for administration by injection. The composition may be an aqueous composition. The composition may further comprise pharmaceutically acceptable excipients. The composition may further comprise an excipient selected from the group consisting of pharmaceutically acceptable salts, polysaccharides, peptides, proteins, amino acids, synthetic polymers, natural polymers, and surfactants. The viral vector, such as AAV, may be suspended in a buffer, such as PBS. The buffer, such as PBS, may comprise surfactant such as about 0.01% pluronic F68 surfactant.
[0028] The gene therapy administrations may be a single administration, or the gene therapy administrations may be repeated, for example the gene therapy administration may be repeated daily, weekly, monthly, bi-annually or annually. Where the gene therapy administration is local, such as to a specific muscle, the gene therapy administration may comprise multiple administrations to the same subject to different areas of their body.
[0029] Direct local administration of BDNF and / or GDNF
[0030] In one embodiment the treatment or prevention of CMT comprises the direct local administration of BDNF and / or GDNF protein. The local administration may be by injection. The injection may be an injection of BDNF and / or GDNF directly into a tissue, such as intramuscular injection. The BDNF and / or GDNF may not be administered systemically, such as intravenously.
[0031] Advantageously, it has been demonstrated herein that intramuscular administration of BDNF or GDNF rescues GarsAETAa / +endosome in vivo transport to physiological levels. Downstream pro-survival pathways are shared between BDNF and GDNF. Direct local administration of BDNF and / or GDNF is likely to provide beneficial therapy for CMT and other ARS-related CMTs, as similar mechanisms of secretion and structural relaxation occur.
[0032] The administration may be targeted to any or all muscles of the body. In one embodiment, the administration may be targeted to one or more of the muscles of the hands (such as the thenar eminence), feet (such as the extensor digitorum brevis), arms (such as the flexor carpi ulnaris) and / or legs (such as the tibialis anterior). The administration may be targeted to a specific nerve or muscle, or tissues surrounding a targeted nerve or tissue. The targeted nerve may be a motor or sensory neuron. The targeted nerve may be one or more of the sciatic, median, ulnar or radial nerves. The administration may not be into the CNS (e.g. brain and spinal cord).
[0033] The BDNF and / or GDNF may be in a composition. The BDNF and / or GDNF may be formulated for administration by injection. The composition may further comprise pharmaceutically acceptable excipients. The composition may further comprise an excipient selected from the group consisting of pharmaceutically acceptable salts, polysaccharides, peptides, proteins, amino acids, synthetic polymers, natural polymers, and surfactants.
[0034] The direct local administration may be a single administration, or the direct local administration may be repeated, for example the direct local administration may be repeated daily, weekly, monthly, bi- annually or annually. Where the direct local administration is local, such as to a specific muscle, the administration may comprise multiple administrations to the same subject to different areas of their body.
[0035] The BDNF
[0036] The BDNF may be recombinant. Additionally or alternatively, the BDNF may be human. Preferably, the BDNF is a recombinant human protein.
[0037] The BDNF may comprise or consist of the sequence of SEQ ID NO: 4 or 5, or a functional variant thereof. The BDNF may be encoded by a sequence comprising or consisting of the sequence of SEQ. ID NO: 3 or 6, or a variant thereof encoding a functional BDNF.
[0038] The skilled person will understand that variants of BDNF may be available, where the variant is still functional. Such variants may have 1, 2, 3, 4, 5 or more residue substitutions, deletions, or additions, without eliminating the BDNF function. The substitutions may be for similar amino acids having equivalent charge, size or hydrophobicity (e.g. conservative substitutions). Variants of BDNF may comprise protein sequences having at least 70% sequence identity with the wild-type BDNF according to SEQ ID NO: 4 or 5. In another embodiment, variants of the BDNF may comprise protein sequences having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the wild-type BDNF according to SEQ ID NO: 4 or 5. Additionally or alternatively, variants of the BDNF may comprise truncations relative to the wild-type BDNF.
[0039] Nucleotide sequences encoding the BDNF, such as SEQ ID NO: 3 or 6, may be varied, for example by the use of codon-redundancy or codon optimisaton. The variant nucleotide sequence may comprise alternative codons, which still encode the functional BDNF as described herein. The BDNF may be encoded by a sequence comprising or consisting of the sequence having at least 60% sequence identity to SEQ ID NO: 3 or 6. In another embodiment, the BDNF may be encoded by a sequence comprising or consisting of the sequence having at least 70% sequence identity to SEQ ID NO: 3 or 6. In another embodiment, the BDNF may be encoded by a sequence comprising or consisting of the sequence having at least 80% sequence identity to SEQ ID NO: 3 or 6. In another embodiment, the BDNF may be encoded by a sequence comprising or consisting of the sequence having at least 90% sequence identity to SEQ ID NO: 3 or 6. In another embodiment, the BDNF may be encoded by a sequence comprising or consisting of the sequence having at least 95% sequence identity to SEQ ID NO: 3 or 6. In another embodiment, the BDNF may be encoded by a sequence comprising or consisting of the sequence having at least 98% sequence identity to SEQ ID NO: 3 or 6.
[0040] The skilled person will recognise that there are several known BDNF polymorphisms, for example as described by Shen et al. (Aging Dis 9: 523-536 (2018) https: / / doi.org / 10.14336 / AD.2017.0717), which is herein incorporated by reference. Therefore, the variant may comprise such BDNF polymorphisms.
[0041] The BDNF sequences described herein may or may not comprise the signal peptide sequence. In another embodiment, the pre- and the pro- sequence is removed. In one embodiment, the signal peptide is substituted for another signal peptide sequence, such as an artificial signal peptide sequence. In another embodiment, the signal peptide, the pre- and the pro- sequence is substituted for another signal peptide sequence, such as an artificial peptide signal peptide sequence. The skilled person will be familiar with suitable signal peptide sequences. For example, the artificial signal peptide sequence of MWWRLWWLLLLLLLLWPMVWA (SEQ. ID NO: 7) may be used, e.g. as described in Guler- Gane et al. (PLoS One 11: e0155340 (2016) https: / / doi.org / 10.1371 / journal.pone.0155340), which is incorporated herein by reference.
[0042] The GDNF
[0043] The GDNF may be recombinant. Additionally or alternatively, the GDNF may be human. Preferably, the GDNF is a recombinant human protein.
[0044] The GDNF may comprise or consist of the sequence of SEQ ID NO: 9 or 10, or a functional variant thereof. The GDNF may be encoded by a sequence comprising or consisting of the sequence of SEQ ID NO: 8, or a variant thereof encoding a functional GDNF.
[0045] The skilled person will understand that variants of GDNF may be available, where the variant is still functional. Such variants may have 1, 2, 3, 4, 5 or more residue substitutions, deletions, or additions, without eliminating the GDNF function. The substitutions may be for similar amino acids having equivalent charge, size or hydrophobicity (e.g. conservative substitutions). Variants of GDNF may comprise protein sequences having at least 70% sequence identity with the wild-type GDNF according to SEQ ID NO: 9 or 10. In another embodiment, variants of the GDNF may comprise protein sequences having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the wild-type GDNF according to SEQ ID NO: 9 or 10. Additionally or alternatively, variants of the GDNF may comprise truncations relative to the wild-type BDNF.
[0046] Nucleotide sequences encoding the GDNF, such as SEQ. ID NO: 8, may be varied, for example by the use of codon-redundancy or codon optimisaton. The variant nucleotide sequence may comprise alternative codons, which still encode the functional GDNF as described herein. The GDNF may be encoded by a sequence comprising or consisting of the sequence having at least 60% sequence identity to SEQ ID NO: 8. In another embodiment, the GDNF may be encoded by a sequence comprising or consisting of the sequence having at least 70% sequence identity to SEQ ID NO: 8. In another embodiment, the GDNF may be encoded by a sequence comprising or consisting of the sequence having at least 80% sequence identity to SEQ ID NO: 8. In another embodiment, the GDNF may be encoded by a sequence comprising or consisting of the sequence having at least 90% sequence identity to SEQ ID NO: 8 In another embodiment, the GDNF may be encoded by a sequence comprising or consisting of the sequence having at least 95% sequence identity to SEQ ID NO: 8. In another embodiment, the GDNF may be encoded by a sequence comprising or consisting of the sequence having at least 98% sequence identity to SEQ ID NO: 8.
[0047] The skilled person will recognise that there are several known GDNF polymorphisms, for example as described in the NCBI database (htt :Z www.ncbi^ which is herein incorporated by reference. Therefore, the variant may comprise such GDNF polymorphisms.
[0048] The GDNF sequences described herein may or may not comprise the signal peptide sequence. In another embodiment, the pre- and the pro- sequence is removed. In one embodiment, the signal peptide is substituted for another signal peptide sequence, such as an artificial signal peptide sequence. In another embodiment, the signal peptide, the pre- and the pro- sequence is substituted for another signal peptide sequence, such as an artificial peptide signal peptide sequence. The skilled person will be familiar with suitable signal peptide sequences. For example, the artificial signal peptide sequence of MWWRLWWLLLLLLLLWPMVWA (SEQ ID NO: 7) may be used, e.g. as described in Guler- Gane et al. (PLoS One 11: e0155340 (2016) https: / / doi.org / 10.1371 / journal.pone.0155340), which is incorporated herein by reference.
[0049] The Disease The disease to be treated or prevented may be Charcot-Marie-Tooth (CMT) disease. In one embodiment the CMT is an ARS-related CMT. The skilled person will recognize that ARS-related CMT is a subtype of CMT wherein an aminoacyl-tRNA synthetase (ARS) have been implicated in the CMT disease with an axonal pathogenesis. Glycyl-tRNA synthetase is implicated in CMT type 2D (CMT2D), tyrosyl-tRNA synthetase is implicated in dominant intermediate CMT type C (DI-CMTC), alanyl-tRNA synthetase is implicated in CMT type 2N (CMT2N), and lysyl-tRNA synthetase is implicated in CMT intermediate recessive type B (CMTIRB). The CMT disease may be selected from CMT2D, CMTDIC, CMT2N, and CMTIRB; or combinations thereof. The CMT may be AARS1 related CMT2N, GARS1 related CMT2D and / or dSMAV, HARS1 related CMT2W, MARS1 related CMT2, WARSI related CMT (currently undesignated), or YAR1S related DI-CMTC.
[0050] In one embodiment, the CMT disease is the CMT2D subtype. In another embodiment, the CMT disease is the DI-CMTC subtype.
[0051] The subject
[0052] The subject may be a mammal. The subject may be human. The subject may have CMT (e.g. diagnosed with CMT or suspected thereof), such as CMT2D, or any of the CMT subtypes described herein. The subject may be at risk of developing CMT, such as CMT2D or any of the CMT subtypes described herein. In an alternative embodiment, the subject may be a non-human animal, such as a domestic animal or livestock.
[0053] Combination Therapy
[0054] The use of the BDNF and / or GDNF the treatment or prevention of Charcot-Marie-Tooth disease (CMT) may be in combination with one or more other therapeutically active agents, such as growth factors. In one embodiment, the use is in combination with one or more neurotrophins. In one embodiment, the use is in combination with NT-3 and / or VEGFiss therapy. The neurotrophin therapy may be delivered genetically for expression via a viral vector, such as AAV, e.g. AAV1, or by direct injection. NT-3 gene therapy is described by Ozes et al. (Brain Commun 3: fcab252 (2021) https: / / doi.org / 10.1093 / braincomms / fcab252), which is herein incorporated by reference. The VEGFiss therapy may be delivered genetically for expression via a viral vector, such as lentivirus, or by direct injection. VEGFiss gene therapy is described by He et al. (Nature 526: 710-4 (2015) https: / / doi.org / 10.1038 / naturel5510), which is herein incorporated by reference. Other Aspects
[0055] According to another aspect of the present invention, there is provided a nucleic acid encoding BDNF and / or GDNF and a muscle-specific promoter.
[0056] In one embodiment, the muscle-specific promoter is for controlling the expression of the BDNF and / or GDNF, for example in a cell.
[0057] The nucleic acid may be the nucleic acid described herein for the treatment or prevention of CMT. In a preferred embodiment, the nucleic acid is a viral vector. The nucleic acid may comprise SEQ ID NO: 11, or the substituted viral vector variants of SEQ. ID NO: 11 described herein. The nucleic acid may be in a virus particle, such as an AAV virus particle.
[0058] The nucleic acid may further encode one or more growth factors. The growth factors may comprise neurotrophin, such as NT-3, and / or VEGFiss-
[0059] According to another aspect of the present invention, there is provided a viral vector comprising the nucleic acid of the invention.
[0060] According to another aspect of the present invention, there is provided a virus particle, or virus like- particle (VLP) comprising the nucleic acid of the invention.
[0061] According to another aspect of the present invention, there is provided a composition comprising the nucleic acid, viral vector, viral particle or VLP according the invention, and a carrier.
[0062] The composition may further comprise nucleic acid encoding one or more growth factors. The growth factors may comprise neurotrophin, such as NT-3, and / or VEGFiss- The nucleic acid encoding one or more growth factors may be in a viral vector, such as an AAV or lentiviral vector. The nucleic acid encoding one or more growth factors may be in a virus particle, such as AAV or lentivirus.
[0063] According to another aspect of the present invention, there is provided a composition comprising a) recombinant BDNF and / or GDNF; b) one or more growth factors or nucleic acid encoding one or more growth factors; and c) a pharmaceutically acceptable carrier. The growth factors may comprise neurotrophin, such as NT-3, and / or VEGFiss-
[0064] The nucleic acid encoding one or more growth factors may be in a viral vector, such as AAV or lentivirus.
[0065] The composition may be a pharmaceutically acceptable composition.
[0066] According to another aspect of the invention, there is provided a method of manufacturing the nucleic acid according to the invention, the method comprising the insertion of a muscle-specific promoter sequence into a nucleic acid with a sequence encoding BDNF and / or GDNF.
[0067] The muscle-specific promoter may control the expression of the BDNF and / or GDNF, for example in a cell.
[0068] According to another aspect of the present invention, there is provided a method of treatment or prophylaxis of a subject for Charcot-Marie-Tooth disease (CMT), wherein the treatment or prophylaxis comprises:
[0069] - the administration of BDNF and / or GDNF to the subject; and / or
[0070] - the administration of nucleic acid encoding BDNF and / or GDNF to the subject.
[0071] The nucleic acid encoding BDNF and / or GDNF may be in accordance with the invention herein. The BDNF and / or GDNF for administration may be in a composition, such as a pharmaceutically acceptable composition. The nucleic acid encoding BDNF and / or GDNF may be in the composition, the viral vector, the virus particle or the VLP accordance with the invention herein.
[0072] The administration of BDNF and / or GDNF to the subject; and / or the administration of nucleic acid encoding BDNF and / or GDNF to the subject may be in an amount sufficient to provide a therapeutic effect.
[0073] The amount sufficient to provide a therapeutic effect may be up to 3.0 x io12vg / kg or up to 2.0 x io14vg / kg for intravenous injection. Intravenous injections may be dosed between 1.0 x io12vg / kg and 2.0 x 1014vg / kg. For intramuscular injections into CMT patients, a concentration of up to 6.0 x io12vg / kg may be injected. Intramuscular injections may be dosed between 1.0 x io11vg / kg and 6.0 x io12vg / kg. According to another aspect of the present invention, there is provided the use of BDNF and / or GDNF, or the composition according to the invention, or the nucleic acid according to the invention for the treatment or prevention of CMT.
[0074] According to another aspect of the present invention, there is provided a kit comprising the nucleic acid, the composition, the viral vector, the virus particle or the VLP accordance with the invention herein, and optionally one or more syringes.
[0075] The nucleic acid, the composition, the viral vector, the virus particle or the VLP accordance with the invention may be pre-loaded in the syringe(s). For combination therapy, each therapy may be provided in a separate syringe.
[0076] The kit may further comprise instructions for local administration of the nucleic acid, the composition, the viral vector, the virus particle or the VLP accordance with the invention at a specific tissue site of a subject, such as a muscle.
[0077] Definitions
[0078] The terms "treatment" or "therapy" are understood to mean at least a reduction in progression of the disease or a recovery from the disease. In some embodiments, the subject's symptoms of the disease may be fully or partially alleviated. The treatment effect may be permanent or temporary.
[0079] The term "localised", "local delivery", "local administration" or "localised treatment" or similar, is intended to refer to the administration of treatment directly into a muscle or muscles, for example by injection into the effected tissue. The treatment may not be administered systemically.
[0080] The term "gene therapy" is understood to be the introduction of genetic material, such as genes and / or regulatory elements, into a cell or cells of a subject to provide a therapeutic benefit or prevent a condition or disease. The genetic material may be for transient or stable expression.
[0081] The skilled person will understand that variants of a given protein or amino acid sequence may be available, where the variant is still functional. Such variants may have 1, 2, 3, 4, 5 or more residue substitutions, deletions, or additions, without eliminating the original / wild-type function. The substitutions may be for similar amino acids having equivalent charge, size or hydrophobicity (e.g. conservative substitutions). Variants may comprise protein sequences having at least 70% sequence identity with the wild-type sequence. In another embodiment, variants may comprise protein sequences having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the wild-type sequence. Additionally or alternatively, variants of the protein may comprise truncations relative to the wild-type.
[0082] The skilled person will understand that variants of a given nucleic acid sequence may be available, where the variant is still functional. Such variants may have 1, 2, 3, 4, 5 or more base pair substitutions, deletions, or additions, without eliminating the original / wild-type function. The substitutions may be for an alternative codon, which encodes the same amino acid residue as the original / wild-type sequence ( / .e., codon redundancy). Variants may comprise nucleic acid sequences having at least 70% sequence identity with the wild-type sequence. In another embodiment, variants may comprise nucleic acid sequences having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the wild-type sequence. Additionally or alternatively, variants of the nucleic acid may comprise truncations or splice variants relative to the wild-type / original sequence.
[0083] Sequence identity may be determined by standard BLAST alignment parameters (provided by http: / / www.ncbi.nlm.nih.gov / ).
[0084] The skilled person will understand that optional features of one embodiment or aspect of the invention may be applicable, where appropriate, to other embodiments or aspects of the invention.
[0085] Embodiments of the invention will now be described in more detail, by way of example only, with reference to the accompanying drawings.
[0086] Figure 1. Neuropathy-causing GARS1 mutations impair retrograde axonal transport of signalling endosomes in vivo. (A) Intramuscular injection of a fluorescent fragment of tetanus neurotoxin (HcT- 555), with subsequent exposure of the sciatic nerve, permits in vivo imaging of signalling endosomes in intact peripheral nerve axons of live, anaesthetised mice. Retrogradely transported HcT-positive endosomes are individually tracked to quantitatively assess their dynamics. Shaded arrowheads identify two different endosomes. Scale bar = 10 pm. (B) Endosome frame-to-frame speed histograms of 1 month-old (P30-P38) wild-type and CMT2D-modelling GarsAETAQ / +mice. (C) GarsAETAQ / +mice display a deficit in signalling endosome axonal transport speeds at both 1 (P30-P38) and 3 months (P88-P95) of age (genotype P < 0.001, age P = 0.671, interaction P = 0.531 two-way ANOVA). n = 6. (D) Endosome frame-to-frame speed histograms of 1 month-old (P33-P37) wild-type mice receiving intramuscular injections of recombinant human wild-type (left graph) or CMT2D-causing (right graph) GlyRS variants compared to vehicle control. (E-G) GlyRSL129pand GlyRSG240R, but not GlyRSWT, cause a non-cell autonomous decrease in signalling endosome speed (E, P < 0.001 one-way ANOVA), increased pause time (F, P < 0.001 one-way ANOVA) and more pausing endosomes (G, P < 0.001 one-way ANOVA) in healthy axons, n = 5-6. For all graphs, *P < 0.05, **P < 0.01, ***p < 0.001 Sidak's multiple comparisons test; means ± SEM plotted.
[0087] Figure 2. GlyRSAETAQaberrantly interacts with the extracellular domain of TrkB. (A) Representative western blots from in vitro pull-downs in NSC-34 cells showing that human mutant GlyRSAETAQ, but not GlyRSWT, interacts with the extracellular domain of human TrkB-Fc. IP, immunoprecipitation. (B) Quantification of the relative interactions between GlyRSWTand GlyRSAETAQwith TrkB-Fc. n = 3. (C) Western blot of lumbar (L1-L5) DRG lysates from wild-type and GarsAETAQ / +mice aged P82-P143. Samples were probed with antibodies against several proteins (NF200, peripherin, TrkB and GlyRS) that are altered in lumbar DRG of other mutant Gars alleles. (D) Densitometric analyses of the western blots in panel C show that levels of total NF200 and full-length TrkB (FL-TrkB) are reduced, and levels of peripherin and GlyRS are increased in GarsAETAQ / +lumbar ganglia. 200 kDa NF200 (P = 0.063), truncated TrkB (TrkB.tl, P = 0.493) and total TrkB (P = 0.462) remain unaltered, n = 5-6. For all graphs, *P < 0.05, **P < 0.01, ***P < 0.001 unpaired t-test; means ± SEM plotted.
[0088] Figure 3. In vivo axonal transport is selectively impaired in YarsE196Khomozygous mice at 9 months. (A) Frame-to-frame speed histogram of signalling endosomes being transported within motor neurons innervating the gastrocnemius muscle of wild-type, YarsE196K / +and YarsE196l< / E196l<mice aged 9 months (P267-P279). (B-D) There is no difference between genotypes in signalling endosome speed (B, P = 0.971), percentage time paused (C, P = 0.848) or the percentage of pausing endosomes (D, P = 0.529 Kruskal l-Wal lis test) in neurons innervating the gastrocnemius. (E) Frame-to-frame speed histogram of signalling endosomes being transported within motor neurons innervating the tibialis anterior muscle of wild-type, YarsE196K / +and YarsE196l< / E196l<mice aged 9 months. (F) Signalling endosome speed is reduced in tibialis anterior axons of YarsE196l< / E196l<mice (P = 0.007). (G and H) The percentage time paused is unaffected (G, P = 0.053), but the percentage of pausing endosomes is increased (H, P = 0.014) in tibialis anterior axons of YarsE196l< / E196l<mice. Endosomes within tibialis anterior- and gastrocnemius-innervating axons were analysed from the same mice. Genotypes were compared using one-way ANOVAs, unless otherwise stated. For all graphs, n = 6-8; *P < 0.05 Sidak's multiple comparisons test; means ± SEM plotted. Figure 4. The YARS1E196Kmutation causes mutant TyrRS to aberrantly interact with TrkB. (A) Representative western blots from in vitro pull-downs in NSC-34 cells showing that human TyrRSE196Kaberrantly interacts with the extracellular domain of human TrkB-Fc. GlyRSAETAQwas used as a positive control. IP, immunoprecipitation. (B) Quantification of the relative interactions between TyrRSWT, TyrRSE196Kand GlyRSAETAQwith TrkB-Fc (P < 0.001 one-way ANOVA; **P < 0.01, ***P < 0.001 Sidak's multiple comparisons test), n = 3. Means ± SEM plotted.
[0089] Figure 5. In vivo BDNF depletion and TrkB inhibition impair endosome transport via ERK1 / 2. (A) Endosome frame-to-frame speed histograms of wild-type mice 4-8 h post-treatment with intramuscular injections of anti-BDNF or IgY control antibody. (B) Anti-BDNF slows wild-type endosome transport (***P < 0.001 unpaired t-test). n = 5-6. (C and D) Intramuscular injection of 50 nM pan-Trk inhibitor, PF-06273340, slows signalling endosome transport in wild-type motor axons (*P < 0.05 unpaired t-test). n = 5-6. (E and F) Intramuscular injection of 50 nM ERK1 / 2 inhibitor, refametinib, also impairs endosome transport in wild-type mice (**P < 0.01 unpaired t-test). n = 3. For all graphs, mice were P29-P45; means ± SEM plotted.
[0090] Figure 6. ERK1 / 2 inhibition and BDNF sequestration act locally, not systemically, to impair axonal transport of signalling endosomes. (A) Schematic depicting the dual-injection paradigm used in experiments designed to assess whether refametinib acts locally within the injected muscle or systemically, thus impacting transport in the contralateral sciatic nerve. Injections were performed 4- 8 h prior to imaging endosome transport. (B) Endosome frame-to-frame speed histograms of wildtype mice treated intramuscularly with vehicle (DMSO) into one side of the body and 50 nM refametinib into the other. (C) Endosomes only slowed in axons with terminals exposed to refametinib (*P = 0.0254), indicating that ERK1 / 2 is inhibited only locally. (D and E) Refametinib does not significantly affect endosome pausing (D, P = 0.098; E, P = 0.131). (F) Schematic depicting the dualinjection paradigm used to assess whether anti-BDNF acts locally or systemically. Injections were performed 4-8 h prior to imaging endosome transport. (G) Endosome frame-to-frame speed histograms of wild-type mice treated with intramuscular injections of 250 ng IgY or anti-BDNF. (H-J) Anti-BDNF antibodies impair transport only in axons with terminals innervating the injected muscles (H, *P = 0.023; I, P = 0.073; J, *P = 0.046). For all graphs, mice were P32-P54; data were compared using paired t-tests; n = 5-6 ; means ± SEM plotted. Figure 7. Augmenting BDNF in CMT2D and DI-CMTC muscles restores in vivo axonal transport. (A) Endosome frame-to-frame speed histograms of 1 month-old (lm; P30-P38) wild-type and GarsAETAa / +mice 4-8 h post-treatment with intramuscular injections of vehicle or 25 ng recombinant BDNF (left graph). BDNF rescues in vivo axonal transport of signalling endosomes in GarsAETAa / +mice (right graph, P < 0.001 one-way ANOVA; **P < 0.01, ***p < 0.001 Sidak's multiple comparisons test), n = 6. (B) Frame-to-frame speed histogram of signalling endosomes being transported within motor neurons innervating the tibialis anterior muscle of 9 month-old (9m; P271-P272) YarsE196l< / E196l<mice 4-8 h posttreatment with intramuscular injections of vehicle or 25 ng recombinant BDNF (left graph). BDNF increases the in vivo axonal transport speed of signalling endosomes in YarsE196l< / E196l<(right graph, **P = 0.004 paired t-test). n = 4. (C) Endosome frame-to-frame speed histograms of 1 month-old (lm; P33- P37) wild-type mice 4-8 h post-treatment with intramuscular injections of mutant GlyRS (L129P or G240R) with or without BDNF (left graph). The axonal transport impairment induced by human CMT2D-causing GlyRS is prevented by BDNF (right graph, P < 0.001 Kruskal-Wallis test; *P < 0.05, **P
[0091] < 0.01 Dunn's multiple comparisons test), n = 4-6. For all graphs, means ± SEM plotted.
[0092] Figure 8. Intramuscular injection of GDNF rescues impaired in vivo axonal transport of signalling endosomes in Gars21™0mice. (A) Schematic depicting the dual-tibialis anterior injection paradigm used in experiments to assess the impact of treatment with 25 ng recombinant GDNF in 3 month-old (3m; P97-P102) GarsAETAQ / +mice. (B) Endosome frame-to-frame speed histograms of 3 month-old GarsAETAQ / +mice 4-8 h post-treatment with intramuscular injections of GDNF versus contralateral control injections of vehicle (left graph). Intramuscular injection of GDNF increases signalling endosome axonal transport speed to physiologically normal levels in GarsAETAC1 / +mice (right graph, *P
[0093] < 0.05 paired t-test). For all graphs, n = 4; means ± SEM plotted.
[0094] Figure 9. AAV8-tMCK drives muscle-specific transgene expression. (A) Representative western blot showing selective GFP expression in muscles at P30 from a mouse intraperitoneally injected at P2 with AAV8-tMCK-eGFP. Tissues from a non-injected mouse are provided as controls. These findings were repeated in triplicate. (B and C) Representative single plane, inverted confocal images confirming GFP expression in wholemount muscle fibres at P30 (B) and P82 (C) after intraperitoneal AAV8-tMCK-eGFP injection at P2. These findings were repeated in triplicate. Scale bars = 100 pm. (D-G) Injection of several different concentrations (5.0 x 1010- 2.0 x io11vg / muscle) of AAV8-tMCK-BDNF into the gastrocnemius and tibialis anterior muscles of mice aged Pll resulted in a clear increase in proBDNF in the injected muscles (ipsilateral) by P23 (D and F). No obvious increase in BDNF was observed in contralateral muscles or in the gastrocnemius-adjacent soleus muscle (E). However, the tibialis anterior-adjacent extensor digitorum longus muscle did show increased BDNF (G). These findings were repeated in triplicate. EDL, extensor digitorum longus; GC, gastrocnemius; IP, intraperitoneal; TA, tibialis anterior; vg, vector genomes.
[0095] Figure 10. Intramuscular injection of AAV8-MHCK7-BDNF into Gars21™07* mice rescues in vivo axonal transport of signalling endosomes. (A) Schematic depicting the dual-tibialis anterior (TA) injection paradigm and timeline used in experiments to assess the impact of AAV-MHCK7-BDNF treatment in GarsAETAQ / +mice. (B) Representative western blots of tibialis anterior muscle lysates confirming transgene expression =1 month post-AAV intramuscular injection. mBDNF, mature BDNF. (C) Frame- to-frame speed histogram of signalling endosomes being transported within motor neurons innervating the tibialis anterior muscle of 2 month-old (P61-P62) GarsAETAa / +mice =1 month after bilateral injection of AAV8-MHCK7-eGFP into one tibialis anterior and AAV8-MHCK7-BDNF into the contralateral tibialis anterior (left graph). AAV8-MHCK7-BDNF increases signalling endosome speed in GarsAETAQ / +mice (right graph, **P = 0.007 paired t-test). For all graphs, n = 5; means ± SEM plotted.
[0096] Figure 11. Intramuscular injection of AAV8-tMCK-BDNF into homozygous YarsE196Kmice rescues in vivo axonal transport of signalling endosomes. (A) Schematic depicting the dual-tibialis anterior (TA) injection paradigm and timeline used in experiments to assess the impact of AAV-tMCK-BDNF treatment in YarsE196K / E196Kmice. (B) Frame-to-frame speed histogram of signalling endosomes being transported within motor neurons innervating the tibialis anterior muscle of 9 month-old (9m; P273- P274) YarsE196K / E196Kmice =1 month (29-30 days) after bilateral injection of AAV8-tMCK-eGFP into one tibialis anterior and AAV8-tMCK-BDNF into the contralateral tibialis anterior (left graph). AAV8-tMCK- BDNF increases signalling endosome speed in Ya rsE196K / E196Kmice (right graph, *P = 0.032 paired t-test). For all graphs, n = 4; means ± SEM plotted.
[0097] Figure 12. Intramuscular injection of AAV8-MHCK7-GDNF into Gars21™07* mice rescues in vivo axonal transport of signalling endosomes and increases muscle weight. (A) Schematic depicting the dual- tibialis anterior (TA) injection paradigm and timeline used in experiments to assess the impact of AAV8-MHCK7-GDNF treatment in GarsAETAa / +mice. (B) Frame-to-frame speed histogram of signalling endosomes being transported within motor neurons innervating the tibialis anterior muscle of 2 month-old (P61-P68) GarsAETAQ / +mice =1 month after bilateral injection of AAV8-MHCK7-eGFP into one tibialis anterior and AAV8-MHCK7-GDNF into the contralateral tibialis anterior (left graph). AAV8- MHCK7-GDNF increases signalling endosome speed in GarsAETAa / +mice (right graph, ***p = 0.0005 paired t-test). n = 5. (C) Treatment of GarsAETAQ / +tibialis anterior muscle with AAV8-MHCK7-GDNF results in increased muscle weight compared to AAV8-MHCK7-eGFP (*P = 0.031 paired t-test). n = 13.
[0098] For all graphs, means ± SEM plotted.
[0099] Example 1 - Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D and Dl- CMTC mice
[0100] Summary
[0101] Gain-of-function mutations in the housekeeping genes GARS1 and YARS1, which lead to the expression of toxic versions of glycyl-tRNA (GlyRS) and tyrosyl-tRNA (TyrRS) synthetases, respectively, cause the selective motor and sensory nerve pathology characteristic of Charcot-Marie-Tooth disease (CMT). Aberrant interactions between ARS mutants and different proteins, including neurotrophin receptor TrkB, underlie ARS-linked neuropathies; however, our pathomechanistic understanding of these untreatable peripheral nerve diseases remains incomplete. Through intravital imaging of the sciatic nerve, we show that CMT2D and DI-CMTC mice display early and persistent disturbances in axonal transport of neurotrophin-containing signalling endosomes in vivo. We also confirm that pathological mutant GlyRSAETAQand mutant TyrRSE196Kaberrantly interact with the extracellular domain of neurotrophin receptor TrkB. We discovered that inhibition of this pathway at the nerve-muscle interface perturbs endosome transport in wild-type axons. Accordingly, supplementation of muscles with BDNF, and similar neurotrophic factor GDNF, completely restores physiological axonal transport in neuropathic mice. Together, these findings suggest that selectively targeting muscles with BDNF- and GDNF-boosting therapies could represent a viable therapeutic strategy for ARS-linked neuropathies.
[0102] In this study, we set out to determine whether in vivo disturbances in axonal transport of neurotrophin-containing signalling endosomes contribute to CMT2D and DI-CMTC pathogenesis.
[0103] Results
[0104] CMT2D mice display early, persistent perturbations in endosome axonal transport in vivo
[0105] Injection of a well-characterised atoxic fluorescent fragment of tetanus neurotoxin (HcT-555) (1) into distal leg muscles permits in vivo imaging and tracking of signalling endosomes within intact sciatic nerve axons of live, anaesthetised mice (Figure 1A) (2-4). By imaging thicker axons only, we have previously shown that transport is assessed in motor rather than sensory neurons (5). HcT-555 was injected into wild-type and GarsAETAC1 / +mice, which carry a deletion in endogenous mouse Gars modelling a mutation identified in a patient presenting with severe, early-onset neuropathy (6). The AETAQ. mutation causes progressive motor phenotypes, including neuromuscular junction (NMJ) degeneration, modelling human CMT2D. We found that GarsAETAC1 / +mice exhibit overtly reduced speeds of in vivo endosome transport at both 1 and 3 months of age (Figure 1, B and C).
[0106] To assess the possibility of a shared pathomechanism between all CMT2D mouse models, we confirmed that human GlyRSAETAQaberrantly interacts with the extracellular domain of human TrkB (Figure 2, A and B) and that the GarsAETAa / +strain displays the same perturbation of sensory neuron fate present in other mutant Gars alleles (Figure 2, C and D), i.e., that there is a decrease in NF200 and an increase in peripherin levels in lumbar dorsal root ganglia (DRG) (7, 8).
[0107] To further link transport disruption to the human neuropathy, we pre-mixed and co-injected HcT-555 with purified human wild-type or CMT2D-causing GlyRS protein into distal leg muscles of wild-type mice. GlyRSL129pand GlyRSG240Rwere selected because of the strong human genetic evidence supporting their causative role in neuropathy (9, 10). We found that both mutants, but not GlyRSWT, perturbed transport of signalling endosomes in otherwise healthy peripheral nerve axons of wild-type animals (Figure 1, D-G). This result indicates that extracellular exposure of motor nerve terminals to mutant GlyRS is sufficient to alter axonal endosome trafficking, suggesting the presence of a non-cell autonomous component to this phenotype, as previously identified in a Drosophila CMT2D model, where muscle-derived mutant GlyRS accumulates at NMJs and coincides with motor neuron degeneration (11, 12).
[0108] Together, these findings indicate that neuropathy-causing GARS1 mutations impair axonal transport of neurotrophin-containing signalling endosomes in motor neurons in vivo and that human mutant GlyRS injected into muscle can induce this phenotype in wild-type mice.
[0109] YarsE196K / E196Kmice modelling DI-CMTC also display perturbed in vivo axonal transport
[0110] We next wanted to determine whether deficits in in vivo axonal transport of signalling endosomes is a common feature of ARS-linked neuropathy. We therefore turned to the newly generated YarsE196Kmouse model of DI-CMTC (13), which possesses the E196K patient mutation (c.586G>A) in exon 5 of the mouse Yars gene. The TyrRSE196Kmutation has little effect on tyrosine aminoacylation (14-16), hence YarsE196Kmice can be studied as heterozygotes or homozygotes, unlike mouse models for CMT2D (6, 17, 18). Heterozygous YarsE196K / +mice display little to no neuromuscular phenotype, while motor performance, NCV and motor axon calibres are all reduced by 4 months in homozygous mutants (19). We used HcT to identify whether 9 month-old YarsE196Kmice display an impairment in endosome axonal transport (Figure 3). However, rather than injecting both the tibialis anterior and gastrocnemius muscles together, as we did in GarsAETAC1 / +mice, we performed assessments of transport separately in these two muscles, as we have recently determined that their innervating axons can be differentially affected by disease in a mouse model of amyotrophic lateral sclerosis (20). The most common clinical signs reported in a small cohort of familial DI-CMTC patients were weakness and atrophy of the tibialis anterior and gastrocnemius (21), thus these two muscles appear to be clinically relevant for the transport assessments. In motor neurons innervating the gastrocnemius muscle, we observed no differences between genotypes in signalling endosome speed (Figure 3, A and B), the percentage time that endosomes remained stationary (Figure 3C) or the percentage of endosomes that paused (Figure 3D). However, yarsE196K / E196Kmice displayed a reduction in endosome trafficking speeds in tibialis anterior-innervating neurons, coupled with an increase in the percentage of pausing endosomes (Figure 3, E-H). This suggests that DI-CMTC mice display a muscle-selective disruption in axonal transport and that deficits in endosome axonal trafficking are a common feature in mouse models of ARS-liked neuropathy.
[0111] TyrRSE196Kaberrantly associates with the extracellular domain of TrkB
[0112] We have previously shown that several different forms of human mutant GlyRS aberrantly associate with the extracellular domains (ECDs) of the neurotrophin receptors, TrkA, TrkB and TrkC (7). Neurotrophins are a family of secreted neurotrophic factors that preferentially bind to neuronally- expressed Trk receptors (NGF to TrkA, BDNF and NT / 4 to TrkB and NT-3 to TrkC) to enable local and long-range signalling critical to nerve cell development, differentiation and survival (22). Key to this mis-interaction in vivo, GlyRS is secreted from many different cell types, including neurons and muscle cells, and circulates freely in healthy mouse and human serum (11, 23-25).
[0113] We hypothesise that the mis-interaction between mutant GlyRS and the Trk receptors is contributing to the disruption of signalling endosome axonal transport. Given that we linked Yars mutations to perturbed endosome trafficking (Figure 3), we wanted to determine whether mutant TyrRSE196Kalso aberrantly interacts with the ECD of TrkB, which is the principal neurotrophin receptor at the NMJ (26). To do this, we transfected NSC-34 cells with constructs expressing V5-tagged human YARS1WT, YARS1E196Kor GARS1AETAQ, with the latter included as a positive control. Cells were subsequently lysed and co-immunoprecipitation experiments performed with the ECD of Fc-tagged TrkB (Figure 4A). Western blotting of pull-downs performed in triplicate revealed that TyrRSE196Kdoes indeed mis- interact with TrkB, but to a lesser extent than GlyRSAETAQ(Figure 4B). Importantly for a potential shared pathomechanism with GlyRS, TyrRS is also secreted in vitro and in vivo and is found in serum (27-29).
[0114] Altering BDNF-TrkB signalling at healthy nerve terminals impairs endosome transport
[0115] To test whether dampening BDNF-TrkB signalling at the nerve-muscle interface disrupts endosome transport and thus explains the neuropathic phenotype we observed in both CMT2D and DI-CMTC mice, we co-injected HcT-555 with anti-BDNF antibodies into wild-type leg muscles. This was performed to sequester extracellular BDNF in the vicinity of peripheral nerve terminals and impede signalling through TrkB. Whilst immunoglobulin Y (IgY) control antibodies had no effect on axonal transport, restricting the availability of BDNF at wild-type NMJs resulted in a slow-down in signalling endosome transport (Figure 5, A and B), akin to the neuropathy defect. This indicates that BDNF availability at nerve terminals modulates axonal endosome transport dynamics.
[0116] To corroborate this, we co-injected wild-type muscles with HcT-555 and the selective and peripherally- restricted pan-Trk inhibitor, PF-06273340 (30). PF-06273340 binds to the extracellular domain of Trk receptors, thus restricting their interactions with neurotrophins. Trk inhibition slowed transport in healthy axons of wild-type animals (Figure 5, C and D), thus confirming a role for local Trk signalling in maintaining healthy axonal endosome trafficking.
[0117] There are several key signalling pathways downstream of BDNF-TrkB, including AKT, PLCyl and ERK1 / 2 (22); however, ERK1 / 2 appears to be the most important for regulating endosome axonal transport, at least in vitro (31). To test the hypothesis that impaired ERK1 / 2 activation contributes to compromised endosome transport, we injected the ERK1 / 2 inhibitor, refametinib (32), into wild-type muscles and analysed the axonal transport of signalling endosomes. We found that ERK1 / 2 inhibition caused a stark disruption in trafficking (Figure 5, E and F), confirming the importance of ERK1 / 2 activation for maintaining healthy speeds of signalling endosome axonal transport in motor neurons in vivo.
[0118] To identify whether a local, rather than a systemic, effect of ERK1 / 2 inhibition at distal motor neuron terminals causes transport disruption, we co-administered HcT-555 with refametinib into hindlimb muscles on one side of the body and HcT-555 with vehicle control into the other (Figure 6A), followed by axonal transport measurement. We found that local ERK1 / 2 inhibition within the injected muscle perturbs transport, but has no impact on endosome trafficking in contralateral sciatic nerves (Figure 6, B-E). This result was corroborated by performing similar experiments using IgY control and anti- BDNF antibodies (Figure 6, F-J).
[0119] These data in wild-type mice indicate that perturbation of BDNF-TrkB signalling via ERK1 / 2 inhibition at peripheral nerve terminals is sufficient to disrupt signalling endosome transport in otherwise healthy motor axons, thus replicating the CMT2D phenotype.
[0120] Application of recombinant BDNF to CMT2D and DI-CMTC muscles restores in vivo axonal transport BDNF appears crucial for maintaining axonal dynamics of signalling endosomes generated at peripheral nerve terminals. We thus performed intramuscular injections of recombinant human BDNF and re-assessed endosome transport in the neuropathy models. BDNF treatment at 1 month of age rescued in vivo axonal transport in GarsAETAa / +mice to wild-type levels (Figure 7A). Similarly, BDNF treatment of the tibialis anterior muscle in 9 month-old YarsE196l< / E196l<mice resulted in increased endosome axonal trafficking speeds (Figure 7B). We then administered BDNF to ascertain whether it could restrict the non-cell autonomous disruption of endosome transport caused by human mutant GlyRS. Doing so reversed the transport deficit (Figure 7C), suggesting that boosting BDNF levels can overcome the negative, non-cell autonomous effect on axonal endosome mobility caused by mutant GlyRS at peripheral nerve terminals.
[0121] Application of recombinant GDNF to neuropathic muscles restores in vivo axonal transport
[0122] GDNF is a potent neurotrophic factor for motor neurons that drives activation of intracellular kinase- mediated pathways, which overlap considerably with those elicited by BDNF binding to TrkB (33). We therefore assessed whether injections of recombinant human GDNF could also alleviate in vivo axonal transport dysfunction in GarsAETAC1 / +mice. The CMT2D mice received bilateral injections of vehicle or GDNF into their tibialis anterior muscles at 3 months of age (Figure 8A). Treatment with GDNF was able to enhance in vivo signalling endosome axonal transport to wild-type levels (Figure 8B). These data indicate that like BDNF, boosting GDNF levels in muscle can overcome the negative impact of mutant GlyRS on endosome axonal trafficking.
[0123] Muscle-specific BDNF and GDNF gene therapies rescue axonal transport disruption in CMT mice
[0124] To improve the potential for translation of this discovery, we designed an adeno-associated virus (AAV) to constitutively express BDNF in muscle, thereby avoiding the side-effects of systemic BDNF upregulation (34). AAV serotype 8 (AAV8), which displays efficient muscle tropism (35), was combined with the muscle-specific promoter tMCK (36). First, an AAV8-tMCK-eGFP control virus was shown to selectively express in muscles when injected into the peritoneum of wild-type P2 pups (Figure 9, A-C). After confirming muscle-selectivity of our virus / promoter combination, we performed unilateral injections of AAV8-tMCK-BDNF into the tibialis anterior and gastrocnemius muscles of Pll wild-type mice at several different doses (Figure 9, D-G). At all concentrations tested, we observed a similar robust upregulation of proBDNF in the injected muscles, as well as the adjacent extensor digitorum longus, indicating that our lowest tested dose of 5.0 x io10vector genomes (vg) per muscle was sufficient to maximally express the transgene.
[0125] Having identified a well-tolerated virus dose that drives observable increases in proBDNF expression, we performed bilateral injections of AAV8-BDNF or AAV8-eGFP into the tibialis anterior of 1 month- old GarsAETAa / +mice and 8 month-old YarsE196l< / E196l<mice to analyse the impact on signalling endosome axonal transport after one month of treatment exposure. Similar to the acute improvement driven by intramuscular injections of recombinant BDNF, longer term BDNF treatment with AAV8-BDNF successfully rescued axonal transport of endosomes in both GarsAETAC1 / +(Figure 10) and YarsE196l< / E196l<mice (Figure 11) to wild-type levels.
[0126] We also created an AAV gene therapy to selectively express GDNF in muscle. Intramuscular injection of AAV8-MHCK7-GDNF into one month-old GarsAETAa / +mice resulted in a clear rescue in in vivo axonal transport of signalling endosomes and increased the weight of injected muscles after one month of treatment (Figure 12).
[0127] In conclusion, we have shown that recombinant BDNF can rescue in vivo axonal transport disruption in CMT2D and DI-CMTC mice, that recombinant GDNF is similarly restorative in CMT2D mice, and that muscle-specific gene therapies boosting BDNF and GDNF expression can also overcome trafficking deficits in CMT mice.
[0128] Materials & Methods
[0129] Animals
[0130] Experimentation involving mice was performed under license from the UK Home Office in accordance with the Animals (Scientific Procedures) Act (1986) and was approved by the UCL Queen Square Institute of Neurology Ethical Review Committee. Mice were maintained under a 12 h I ight / dark cycle at constant room temperature (=21°C) with ad libitum water and food (Teklad global 18% protein rodent diet, Envigo, 2018C). Cages were enriched with nesting material, plastic / cardboard tubes and wooden chew sticks as standard, and occasionally with cardboard houses. GarsAETAa / +mice were maintained as heterozygous (male) x wild-type (female) breeding pairs on a C57BL / 6J background and genotyped under standard conditions using forward primer 5'-GGT AGT TTA CTT GTA ACA GGC-3' and reverse primer 5'-TTT CCA ATC TGG GCA GCA GC-3'. YarsE196Kmice maintained as heterozygous x wild- type / heterozygous / homozygous breeding pairs on a C57BL / 6J background and genotyped under standard conditions using the following primers: Yars_F 5' -TGG CTC CAC CCT ATG AGA AC-3', YarsWT_R 5' -AAA CCA CAC CAA CAG CCT TC-3' and YarsE196K_R 5'-CCG CGT TAC TTC CTT TTC C-3'. Both female and male mice were used because no differences in pathology have been observed between sexes. Moreover, axonal signalling endosome dynamics do not differ between female and male wild-type C57BL / 6J mice (5). Post-natal day 1 (Pl) was defined as the day after a litter was first found
[0131] In vivo axonal transport imaging
[0132] Live imaging of signalling endosome axonal transport was performed using an atoxic binding fragment of tetanus neurotoxin (HcT), as described (2-4). For imaging transport in sciatic nerves, HcT-555 was injected into the right lateral gastrocnemius and tibialis anterior muscles of isoflurane-anaesthetised mice, unless otherwise stated. A 10 pl, 26-gauge Hamilton syringe (Sigma, 20779) or a pulled, glass micropipette (Drummond Scientific, 5-000-1001-X10) was used for intramuscular injections. Muscles of the left leg were also injected in experiments designed to assess the site of action of transportaltering treatments (e.g. anti-BDNF and BDNF); the side of administration for vehicles and treatments were alternated between mice to limit biases. 5-7 pg of HcT-555 in phosphate-buffered saline (PBS) was injected per muscle or forepaw in a volume of =1.5-2 pl, before allowing animals to recover from the anaesthesia. 4-8 h post-injection, nerves were exposed under terminal anaesthesia and imaged on an inverted LSM780 laser scanning microscope (Zeiss) within an environmental chamber prewarmed to 37°C. Images (1024x1024, 1% laser power) were acquired every =3 s using a 63x Plan- Apochromat oil immersion objective lens (Zeiss) at 100x digital zoom.
[0133] Intramuscular injections
[0134] Different substances were pre-mixed and co-administered with HcT-555 into the gastrocnemius and tibialis anterior muscles: 25 ng recombinant human glycyl-tRNA synthetase (WT / G240R / L129P), 250 ng chicken IgY anti-BDNF (R&D Systems, AF248), 250 ng chicken control IgY (R&D Systems, AB-101- C), 50 nM PF-06273340 (Sigma, PZ0254) with 25 ng recombinant human BDNF (Peprotech, 450-02), dimethyl sulfoxide (DMSO, Sigma, D1435), 50 nM refametinib (Generon, HY-14691), 25 ng recombinant human BDNF and and 25 ng recombinant human GDNF (Peprotech, 450-10). All amounts are per muscle. Recombinant non-tagged GlyRS was purified as previously described (24). Drug concentrations were selected based on reported IC5o values: 6 / 2 / 1 nM PF-06273340 (TrkA / B / C) (30) and 19 / 47 nM refametinib (ERK1 / ERK2) (32).
[0135] In vivo axonal transport analysis
[0136] Confocal .czi files were uploaded to ImageJ (http: / / rsb.info.nih.gov / ij / ) and endosome dynamics manually tracked using the TrackMate plugin (37). Only endosomes that could be tracked for >5 consecutive frames were analysed. Endosomes that paused for >10 consecutive frames or moved solely anterogradely were excluded. The tracked fraction of endosomes varied depending on how densely populated with fluorescent organelles the axon was (=1-50%); nevertheless, endosomes were selected for assessment as they entered the field of view, without prior observation of their movements. Endosome frame-to-frame speeds are presented in frequency histograms. Endosomes usually take 5-15 frames to traverse the field of view, with rare slower endosomes reaching =30 frames. To determine mean endosome speed per animal, individual endosome speeds were averaged. An endosome was determined to have paused if it remained stationary (within < 0.1 pm) for two consecutive frames. The '% time paused' is a calculation of the time all tracked endosomes remained stationary. The '% pausing endosomes' defines the proportion of endosomes that paused at least once. A minimum of ten endosomes from at least three individual axons was assessed per animal 5- 120 min from initiating anaesthesia (most videos were recorded within 45 min). Thick axons were selected to increase the likelihood of imaging motor, rather than sensory, neurons (5).
[0137] Protein extraction and western blotting
[0138] Tissues for western blotting were dissected from PBS-perfused and non-perfused mice. Lumbar level 1 (LI) to L5 DRG were excised as previously outlined (38, 39). Proteins were extracted from tissues as described (7), except that ground tissue samples were incubated on ice in NP-40 lysis buffer (1% [w / v] NP-40, 50 mM NaCI, 50 mM Tris-HCI [pH 8.0]) for 1-2 h rather than 30 min. Western blotting was performed following published protocols (7), with the following primary antibodies: anti-BDNF (Alomone, ANT-010, 1:500), anti-GFP (Santa Cruz, sc-996, 1:1,000), anti-GlyRS (abeam, ab42905, 1:2,000), anti-NF200 (Sigma, N0142, 1:1,000), anti-peripherin (Chemicon, AB1530, 1:1,000), anti-TrkB (Cell Signaling Technology, 07-225, 1:500), anti-a-tubulin (Cell Signaling Technology, 3873, 1:2,000) and anti-V5 (Thermo Fisher, R960-25, 1:5,000). The following secondary antibodies were then used: anti-mouse IgG-HRP (Sigma, AP308P) and anti-rabbit IgG-HRP (BioRad, 1706515). 20-40 pg of protein from each tissue was loaded per well. Densitometric analysis was performed as previously described (40), using total protein stained with 0.1% Coomassie Brilliant Blue R-250 (Thermo Fisher, 20278) as the loading control (41). In vitro pull-down assay
[0139] The recombinant human TrkB-Fc chimera, consisting of the extracellular domain of TrkB (Cys32-His430; R&D Systems, 688-TK), and control human IgG-Fc (110-HG, R&D Systems) were bound to Dynabeads Protein G (Thermo Fisher, 10003D). Whole cell lysates from NSC-34 cells (CELLutions Biosystems, CLU140) transfected with plasmids encoding human GlyRSWT-V5, GlyRSAETAQ-V5, TyrRSWT- V5, TyrRSE196K-V5 or vector control were added to the beads and incubated overnight at 4°C. The beads were washed twice with wash buffer (25 mM Tris-HCI [pH 7.4], 150 mM NaCI, 1 mM EDTA, 1% [w / v] NP-40, 5% [w / v] glycerol) and treated with sodium dodecyl sulphate loading buffer to elute bound proteins. TrkB-Fc, GlyRS-V5 and TyrRS-V5 were analysed by western blot using anti-human IgG Fc (horseradish peroxidase, pre-adsorbed, abeam, ab89624, 1:10,000) and anti-V5 antibodies, respectively.
[0140] AAV8 virus production
[0141] Self-complementary AAV (scAAV) expression plasmids combining the tMCK and MHCK7 promoters with pre-proBDNF were created by OXGENE (Oxford, UK). scAAV expression plasmids combining the MHCK7 promoter with pre-proGDNF were created by Vector Biolabs (Malvern, PA, USA). A 745 bp tMCK promoter sequence was adapted from those reported by Rodino-Klapac et al. (42) and A 770 bp MHCK7 promoter sequence was obtained from
[0142] Madden et al. (43) and https: / / www.addgene.org / 65042 / sequences / . The 744 bp coding sequence of human pre-proBDNF (ENST00000356660.9) was sourced from Ensembl (CCDS 7866.1) and the 636 bp coding sequence of human pre-proGDNF (ENST00000326524.7) was also sourced from Ensembl (CCDS CCDS3922.1). Plasmids were packaged into AAV serotype 8 particles by Charles River Laboratories (previously Vigene Biosciences).
[0143] AAV8 injections
[0144] Viruses were kept at -80°C in 0.01% (v / v) pluronic F68 surfactant in PBS and diluted in sterile PBS. Viruses were freeze-thawed a maximum of two times before injection. For assessing tissue-specificity of expression, intraperitoneal AAV8-tMCK-eGFP injections were performed on P2 pups using a Hamilton syringe connected to a 30 gauge needle cannula; 7.0 x io10viral genomes (vg) were injected per mouse in a volume of 5 pl. To identify an appropriate dose, intramuscular AAV8 injections were performed with pulled, glass micropipettes directly through the skin into the gastrocnemius and tibialis anterior of Pll pups under isoflurane-induced anaesthesia; 5.0 x io10, 1.0 x io11or 2.0 x io11vg were unilaterally injected into each muscle in a volume of 2.5 pl. To evaluate gene therapy efficacy in GarsAETAa / +mice and YarsE196l< / E196l<mice, bilateral injections into the tibialis anterior muscles were performed under isoflurane-induced anaesthesia. 10 pl bilateral injections of 1.0 to 2.0 x io11vg AAV8- eGFP into one tibialis anterior and 1.0 to 2.0 x 1011vg AAV8-BDNF or AAV8-GDNF into the contralateral tibialis anterior were performed in 1 month-old GarsAETAa / +mice and 8 month-old YarsE196l< / E196l<mice. The side of injection was alternated between mice, and in vivo axonal transport of signalling endosomes was assessed 29-32 days post-AAV treatment, as described above.
[0145] Imaging of GFP in wholemount muscles
[0146] Wholemount muscles (the transversus abdominis [TVA], epitrochleoanconeus [ETA], forelimb lumbrical, hindlimb lumbrical and flexor digitorum brevis [FDB]) were dissected as previously described (44-46). Unfixed muscles obtained from AAV-treated mice at P30 and P82, were mounted in Fluoromount-G (Thermo Fisher, 00-4958-02), covered with 22 x 50 mm cover glass (VWR, 631-0137) and then imaged within 1-3 h of dissection.
[0147] Statistics
[0148] Data were assumed to be normally distributed unless evidence to the contrary were provided by the Kolmogorov-Smirnov test for normality, while equal variance between groups was assumed. Normally-distributed data were statistically analysed using unpaired and paired t-tests or one-way and two-way analysis of variance (ANOVA) tests followed by Sidak's multiple comparisons test. Non- normally distributed data were analysed using Kruskal-Wallis tests followed by Dunn's multiple comparisons tests. Sample sizes, which were pre-determined using power calculations and previous experience, are reported in figure legends and represent biological replicates ( / .e., individual animals). All tests were two-sided and an a-level of P < 0.05 was used to determine significance. GraphPad Prism 9 software (version 9.5.1) was used for statistical analyses and figure production.
[0149] References
[0150] 1. Bercsenyi K, Schmieg N, Bryson JB, Wallace M, Caccin P, Golding M, et al. Tetanus toxin entry. Nidogens are therapeutic targets for the prevention of tetanus. Science. 2014;346(6213):1118-23.
[0151] 2. Gibbs KL, Kalmar B, Sleigh JN, Greensmith L, and Schiavo G. In vivo imaging of axonal transport in murine motor and sensory neurons. J Neurosci Methods. 2016;257:26-33.
[0152] 3. Sleigh JN, Tosolini AP, and Schiavo G. In vivo imaging of anterograde and retrograde axonal transport in rodent peripheral nerves. Methods Mol Biol. 2020;2143:271-92. Tosolini AP, Villarroel-Campos D, Schiavo G, and Sleigh JN. Expanding the toolkit for in vivo imaging of axonal transport. J Vis Exp. 2021(178). Sleigh JN, Tosolini AP, Gordon D, Devoy A, Fratta P, Fisher EMC, et al. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30(ll):3655-62 e2. Morelli KH, Griffin LB, Pyne NK, Wallace LM, Fowler AM, Oprescu SN, et al. Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models. J Clin Invest. 2019;129(12):5568-83. Sleigh JN, Dawes JM, West SJ, Wei N, Spaulding EL, Gomez-Martin A, et al. Trk receptor signaling and sensory neuron fate are perturbed in human neuropathy caused by Gars mutations. Proc Natl Acad Sci U S A. 2017;114(16):E3324-E33. Sleigh JN, Meeh AM, Aktar T, Zhang Y, and Schiavo G. Altered sensory neuron development in CMT2D mice is site-specific and linked to increased GlyRS levels. Front Cell Neurosci. 2020;14:232. Motley WW, Talbot K, and Fischbeck KH. GARS axonopathy: not every neuron's cup of tRNA. Trends Neurosci. 2010;33(2):59-66. Wei N, Zhang Q, and Yang XL. Neurodegenerative Charcot-Marie-Tooth disease as a case study to decipher novel functions of aminoacyl-tRNA synthetases. J Biol Chem. 2019;294(14):5321- 39. Grice SJ, Sleigh JN, Motley WW, Liu JL, Burgess RW, Talbot K, et al. Dominant, toxic gain-of- function mutations in gars lead to non-cell autonomous neuropathology. Hum Mol Genet. 2015;24(15):4397-406. Grice SJ, Sleigh J N, and Zameel Cader M. Plexin-Semaphorin Signaling Modifies Neuromuscular Defects in a Drosophila Model of Peripheral Neuropathy. Front Mol Neurosci. 2018;ll:55. Spaulding EL, Hines TJ, Bais P, Tadenev ALD, Schneider R, Jewett D, et al. The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy. Science. 2021;373(6559):1156-61. Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, Dewil M, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot- Marie-Tooth neuropathy. Nat Genet. 2006;38(2):197-202. Storkebaum E, Leitao-Goncalves R, Godenschwege T, Nangle L, Mejia M, Bosmans I, et al. Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy. Proc Natl Acad Sci U SA. 2009;106(28):11782-7. Froelich CA, and First EA. Dominant Intermediate Charcot-Marie-Tooth disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase. Biochemistry. 2011;50(33):7132-45. Achilli F, Bros-Facer V, Williams HP, Banks GT, AIQatari M, Chia R, et al. An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. Dis Model Meeh. 2009;2(7-8):359-73. Seburn KL, Nangle LA, Cox GA, Schimmel P, and Burgess RW. An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model. Neuron. 2006;51(6):715-26. Hines TJ, Tadenev ALD, Lone MA, Hatton CL, Bagasrawala I, Stum MG, et al. Precision mouse models of Yars / dominant intermediate Charcot-Marie-Tooth disease type C and Sptlcl / hereditary sensory and autonomic neuropathy type 1. J Anat. 2022;241(5):1169-85. Tosolini AP, Sleigh JN, Surana S, Rhymes ER, Cahalan SD, and Schiavo G. BDNF-dependent modulation of axonal transport is selectively impaired in ALS. Acta Neuropathol Commun. 2022;10(l):121. Pan Y, Kafaie J, and Thomas FP. Longitudinal 16-year study of dominant intermediate CMT type C neuropathy. Muscle Nerve. 2020;61(l):lll-5. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4(4):299-309. Park MC, Kang T, Jin D, Han JM, Kim SB, Park YJ, et al. Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis. Proc Natl Acad Sci U S A. 2012;109(ll):E640-7. He W, Bai G, Zhou H, Wei N, White NM, Lauer J, et al. CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. Nature. 2015;526(7575):710-4. Goughnour PC, Park MC, Kim SB, Jun S, Yang WS, Chae S, et al. Extracellular vesicles derived from macrophages display glycyl-tRNA synthetase 1 and exhibit anti-cancer activity. J Extracell Vesicles. 2020;10(l):el2029. Gonzalez M, Ruggiero FP, Chang Q, Shi YJ, Rich MM, Kraner S, et al. Disruption of Trkb- mediated signaling induces disassembly of postsynaptic receptor clusters at neuromuscular junctions. Neuron. 1999;24(3):567-83. Grube L, Dellen R, Kruse F, Schwender H, Stuhler K, and Poschmann G. Mining the Secretome of C2C12 Muscle Cells: Data Dependent Experimental Approach To Analyze Protein Secretion Using Label-Free Quantification and Peptide Based Analysis. J Proteome Res. 2018;17(2):879-
[0153] 90. Casas-Tinto S, Lolo FN, and Moreno E. Active JNK-dependent secretion of Drosophila Tyrosyl- tRNA synthetase by loser cells recruits haemocytes during cell competition. Nat Commun. 2015;6:10022. Schwenk JM, Omenn GS, Sun Z, Campbell DS, Baker MS, Overall CM, et al. The Human Plasma Proteome Draft of 2017: Building on the Human Plasma PeptideAtlas from Mass Spectrometry and Complementary Assays. J Proteome Res. 2017;16(12):4299-310. Skerratt SE, Andrews M, Bagal SK, Bilsland J, Brown D, Bungay PJ, et al. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. J Med Chem. 2016;59(22):10084-99. Mitchell DJ, Blasier KR, Jeffery ED, Ross MW, Pullikuth AK, Suo D, et al. Trk activation of the ERK1 / 2 kinase pathway stimulates intermediate chain phosphorylation and recruits cytoplasmic dynein to signaling endosomes for retrograde axonal transport. J Neurosci. 2012;32(44):15495-510. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, et al. RDEA119 / BAY 869766: a potent, selective, allosteric inhibitor of MEK1 / 2 for the treatment of cancer. Cancer Res. 2009;69(17):6839-47. Cintron-Colon AF, Almeida-Alves G, Boynton AM, and Spitsbergen JM. GDNF synthesis, signaling, and retrograde transport in motor neurons. Cell Tissue Res. 2020;382(l):47-56. Binder DK, Croll SD, Gall CM, and Scharfman HE. BDNF and epilepsy: too much of a good thing? Trends Neurosci. 2001;24(l):47-53. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005;23(3):321-8. Wang B, Li J, Fu FH, Chen C, Zhu X, Zhou L, et al. Construction and analysis of compact musclespecific promoters for AAV vectors. Gene Ther. 2008;15(22):1489-99. Tinevez JY, Perry N, Schindelin J, Hoopes GM, Reynolds GD, Laplantine E, et al. TrackMate: An open and extensible platform for single-particle tracking. Methods. 2017;115:80-90. Sleigh JN, Weir GA, and Schiavo G. A simple, step-by-step dissection protocol for the rapid isolation of mouse dorsal root ganglia. BMC Res Notes. 2016;9:82. Sleigh JN, West SJ, and Schiavo G. A video protocol for rapid dissection of mouse dorsal root ganglia from defined spinal levels. BMC Res Notes. 2020;13(l):302. Sleigh JN, Barreiro-Iglesias A, Oliver PL, Biba A, Becker T, Davies KE, et al. Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Hum Mol Genet. 2014;23(4):855-69. 41. Welinder C, and Ekblad L. Coomassie staining as loading control in Western blot analysis. J Proteome Res. 2011;10(3):1416-9.
[0154] 42. Rodino-Klapac LR, Lee JS, Mulligan RC, Clark KR, and Mendell JR. Lack of toxicity of alpha- sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology. 2008;71(4):240-7.
[0155] 43. Madden L, Juhas M, Kraus WE, Truskey GA, and Bursae N. Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs. Elife. 2015;4:e04885.
[0156] 44. Murray L, Gillingwater TH, and Kothary R. Dissection of the transversus abdominis muscle for whole-mount neuromuscular junction analysis. J Vis Exp. 2014(83):e51162.
[0157] 45. Sleigh JN, Burgess RW, Gillingwater TH, and Cader MZ. Morphological analysis of neuromuscular junction development and degeneration in rodent lumbrical muscles. J Neurosci Methods. 2014;227:159-65.
[0158] 46. Villarroel-Campos D, Schiavo G, and Sleigh JN. Dissection, in vivo imaging and analysis of the mouse epitrochleoanconeus muscle. J Anat. 2022;241(5):1108-1119.
[0159] Sequences tMCK promoter sequence (745 bp):
[0160] Original paper: https: / / www.nature.com / articles / gt2008104 AGATCGGAATTCGCCCTTAAGCTAGCCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGAC ACCCGAGATGCCTGGTTATAATTAACCCCAACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTG
[0161] AGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAA CCCTGTCCCTGGTGGGCCCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGA TGCCTGGTTATAATTAACCCCAACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTGAGCGGTTA CCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCC CTGGTGGGCCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGATGCCTGGTT ATAATTAACCCCAACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTGAGCGGTTACCCCACCCC GGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTGGTGGGC CCCTCCCTGGGGACAGCCCCTCCTGGCTAGTCACACCCTGTAGGCTCCTCTATATAACCCAGGGGCACAGGGG CTGCCCCCGGGTCAC (SEQ ID NO: 1).
[0162] MHCK7 Promoter Sequence (770 bp): https: / / www.addgene.org / 65042 / sequences / and https: / / elifesciences.org / articles / 04885 Original paper: https: / / www.sciencedirect.com / science / article / pii / S15250016163128507via%3Dihub
[0163] CTAGAAGCTGCATGTCTAAGCTAGACCCTTCAGATTAAAAATAACTGAGGTAAGGGCCTGGGTAGGGGAGGT
[0164] GGTGTGAGACGCTCCTGTCTCTCCTCTATCTGCCCATCGGCCCTTTGGGGAGGAGGAATGTGCCCAAGGACTA
[0165] AAAAAAGGCCATGGAGCCAGAGGGGCGAGGGCAACAGACCTTTCATGGGCAAACCTTGGGGCCCTGCTGTC
[0166] TAGCATGCCCCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGATGCCTGGT
[0167] TATAATTAACCCAGACATGTGGCTGCCCCCCCCCCCCCAACACCTGCTGCCTCTAAAAATAACCCTGTCCCTGG
[0168] TGGATCCCCTGCATGCGAAGATCTTCGAACAAGGCTGTGGGGGACTGAGGGCAGGCTGTAACAGGCTTGGG
[0169] GGCCAGGGCTTATACGTGCCTGGGACTCCCAAAGTATTACTGTTCCATGTTCCCGGCGAAGGGCCAGCTGTCC
[0170] CCCGCCAGCTAGACTCAGCACTTAGTTTAGGAACCAGTGAGCAAGTCAGCCCTTGGGGCAGCCCATACAAGG
[0171] CCATGGGGCTGGGCAAGCTGCACGCCTGGGTCCGGGGTGGGCACGGTGCCCGGGCAACGAGCTGAAAGCTC
[0172] ATCTGCTCTCAGGGGCCCCTCCCTGGGGACAGCCCCTCCTGGCTAGTCACACCCTGTAGGCTCCTCTATATAAC
[0173] CCAGGGGCACAGGGGCTGCCCTCATTCTACCACCACCTCCACAGCAC (SEQ ID NO: 2).
[0174] BDNF encoding sequence: mRNA - 744 bp
[0175] >ENA | AAA698051 AAA69805.2 Homo sapiens (human) brain-derived neurotrophic factor precursor :
[0176] Location:!..744
[0177] ATGACCATCCTTTTCCTTACTATGGTTATTTCATACTTTGGTTGCATGAAGGCTGCCCCCA7~GAA4GA4GCA4AC
[0178] ATCCGAGGACAAGGTGGCTTGGCCTACCCAGGTGTGCGGACCCATGGGACTCTGGAGAGCGTGAATGGGCCC
[0179] AAGGCAGGTTCAAGAGGCTTGACATCATTGGCTGACACTTTCGAACACGTGATAGAAGAGCTGTTGGATGAG
[0180] GACCAGAAAGTTCGGCCCAATGAAGAAAACAATAAGGACGCAGACTTGTACACGTCCAGGGTGATGCTCAGT
[0181] AGTCAAGTGCCTTTGGAGCCTCCTCTTCTCTTTCTGCTGGAGGAATACAAAAATTACCTAGATGCTGCAAACAT
[0182] GT’CCATGAGGGT’CCGGCGCCACTCTGACCCTGCCCGCCGAGGGGAGCTGAGCGTGTGTGACAGTATTAGTG
[0183] AGTGGGTAACGGCGGCAGACAAAAAGACTGCAGTGGACATGTCGGGCGGGACGGTCACAGTCCTTGAAAA
[0184] GGTCCCTGTATCAAAAGGCCAACTGAAGCAATACTTCTACGAGACCAAGTGCAATCCCATGGGTTACACAA
[0185] AAGAAGGCTGCAGGGGCATAGACAAAAGGCATTGGAACTCCCAGTGCCGAACTACCCAGTCGTACGTGCG
[0186] GGCCCTTACCATGGATAGCAAAAAGAGAATTGGCTGGCGATTCATAAGGATAGACACTTCTTGTGTATGTA
[0187] CATTGACCATTAAAAGGGGAAGATAG (SEQ ID NO: 3)
[0188] Underlining = signal peptide encoding sequence (18 aa)
[0189] Italics = pro-domain (111 aa)
[0190] Bold = mature domain (118 aa, =14 kDa) Encoded BDNF:
[0191] >sp | P23560 | BDNF_HUMAN Brain-derived neurotrophic factor OS=Homo sapiens OX=9606 GN=BDNF PE=1 SV=1
[0192] M \LFL M\Z\SYFGCMKMPMKEANIRGQGGLAYPGVRTHGTLESVNGPKAGSRGLTSLADTFEHVIEELLDEDQK
[0193] VRPNEENNKDADLYTSRVMLSSQVPLEPPLLFLLEEYKNYLDAANMSMRVRRHSDPARRGELS\ / CDS\SE\N\n'AA
[0194] DKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSK
[0195] KRIGWRFIRIDTSCVCTLTIKRGR (SEQ ID NO: 4)
[0196] Underlining = signal peptide encoding sequence (18 aa)
[0197] Italics = pro-domain (111 aa)
[0198] Bold = mature domain (118 aa, =14 kDa)
[0199] Recombinant BDNF protein sequence (Peprotech - https: / / www.peprotech.com / gb / recombinant- humanmurinerat-bdnf):
[0200] MHSDPARRGE LSVCDSISEW VTAADKKTAV DMSGGTVTVL EKVPVSKGQL KQYFYETKCN PMGYTKEGCR GIDKRHWNSQ CRTTQSYVRA LTMDSKKRIG WRFIRIDTSC VCTLTIKRGR (SEQ. ID NO: 5)
[0201] Bold = mature domain (118 aa, =14 kDa)
[0202] A version of BDNF engineered to lack the pro-domain:
[0203] ATGACCATCCTTTTCCTTACTATGGTTATTTCATACTTTGGTTGCATGAAGGCTTCTGACCCTGCCCGCCGAGG
[0204] GGAGCTGAGCGTGTGTGACAGTATTAGTGAGTGGGTAACGGCGGCAGACAAAAAGACTGCAGTGGACAT
[0205] GTCGGGCGGGACGGTCACAGTCCTTGAAAAGGTCCCTGTATCAAAAGGCCAACTGAAGCAATACTTCTACG AGACCAAGTGCAATCCCATGGGTTACACAAAAGAAGGCTGCAGGGGCATAGACAAAAGGCATTGGAACTC
[0206] CCAGTGCCGAACTACCCAGTCGTACGTGCGGGCCCTTACCATGGATAGCAAAAAGAGAATTGGCTGGCGAT TCATAAGGATAGACACTTCTTGTGTATGTACATTGACCATTAAAAGGGGAAGATAG (SEQ ID NO: 6)
[0207] Artificial signal peptide sequence:
[0208] MWWRLWWLLLLLLLLWPMVWA (SEQ ID NO: 7)
[0209] GDNF encoding sequence: mRNA - 636 bp https: / / www.ncbi.nlm.nih.gOv / nuccore / NM_000514.4
[0210] ATGAAGTTATGGGATGTCGTGGCTGTCTGCCTGGTGCTGCTCCACACCGCGTCCGCC7TCCCGC7GCCCGCCG GTAAGAGGCCTCCCGAGGCGCCCGCCGAAGACCGCTCCCTCGGCCGCCGCCGCGCGCCCTTCGCGCTGAGCAG TGA CTCAAA TA TGCCAGA GGA TTA TCCTGA TCAGTTCGA TGA TGTCA TGGA TTTTA TTCAA GCCA CCA TTAAAA GACTGAAAAGGTCACCAGATAAACAAATGGCAGTGCTTCCTAGAAGAGAGCGGAATCGGCAGGCTGCAGC
[0211] TGCCAACCCAGAGAATTCCAGAGGAAAAGGTCGGAGAGGCCAGAGGGGCAAAAACCGGGGTTGTGTCTTA ACTGCAATACATTTAAATGTCACTGACTTGGGTCTGGGCTATGAAACCAAGGAGGAACTGATTTTTAGGTAC TGCAGCGGCTCTTGCGATGCAGCTGAGACAACGTACGACAAAATATTGAAAAACTTATCCAGAAATAGAAG GCTGGTGAGTGACAAAGTAGGGCAGGCATGTTGCAGACCCATCGCCTTTGATGATGACCTGTCGTTTTTAGA
[0212] TGATAACCTGGTTTACCATATTCTAAGAAAGCATTCCGCTAAAAGGTGTGGATGTATCTGA (SEQ ID NO: 8)
[0213] Underlining = signal peptide encoding sequence (19 aa)
[0214] Italics = pro-domain (58 aa)
[0215] Bold = mature domain (134 aa, =15 kDa)
[0216] Encoded GDNF: https: / / www.ncbi.nlm.nih.gOv / protein / CAG46721.l
[0217] MKL\ND\ / \ / / \ / CL\ / LLm / S / FPLPAGKRPPEAPAEDRSLGRRRAPFALSSDSNMPEDYPDQFDDVMDFIQATIKRL / CRSPDKQMAVLPRRERNRQAAAANPENSRGKGRRGQRGKNRGCVLTAIHLNVTDLGLGYETKEELIFRYCSGS
[0218] CDAAETTYDKILKNLSRNRRLVSDKVGQACCRPIAFDDDLSFLDDNLVYHILRKHSAKRCGCI (SEQ. ID NO: 9)
[0219] Underlining = signal peptide encoding sequence (19 aa)
[0220] Italics = pro-domain (58 aa)
[0221] Bold = mature domain (134 aa, =15 kDa)
[0222] Recombinant GDNF sequence (Peprotech - https
[0223] MSPDKQMAVL PRRERNRQAA AANPENSRGK GRRGQRGKNR GCVLTAIHLN VTDLGLGYET KEELIFRYCS GSCDAAETTY DKILKNLSRN RRLVSDKVGQ ACCRPIAFDD DLSFLDDNLV YHILRKHSAK RCGCI (SEQ ID NO: 10)
[0224] Bold = mature domain (134 aa, =15 kDa)
[0225] Sequence of pAAV_MHCK7_hGDNF (SEQ ID NO: 11):
[0226] LOCUS pAAV_MHCK7_hGDNF 4720 bp DNA circular 24-JAN-2023
[0227] DEFINITION synthetic circular DNA
[0228] ACCESSION .
[0229] VERSION
[0230] KEYWORDS pAAV-MHCK7-eGFP
[0231] SOURCE synthetic DNA construct
[0232] ORGANISM recombinant plasmid
[0233] REFERENCE 1 (bases 1 to 4853) AUTHORS .
[0234] TITLE Direct Submission
[0235] JOURNAL Exported Wednesday, Sep 2, 2020 from SnapGene 5.1.5 https: / / www.snapgene.com
[0236] COMMENT
[0237] COMMENT ApEinfo:methylated:l
[0238] FEATURES Location / Qualifiers source 1..158
[0239] / organism="recombinant plasmid"
[0240] / mol_type="other DNA"
[0241] / locus_tag="source:recombinant plasmid"
[0242] / label="source:recombinant plasmid"
[0243] / ApEinfo_label="source:recombinant plasmid"
[0244] / ApEinfo_fwdcolor="pink"
[0245] / ApEinfo_revcolor="pink"
[0246] / ApEinfo_graphicformat="arrow_data {{00.5 0 1 200 -10
[0247] -0.5} {} 0} width 5 offset 0" rep_origin 1..141
[0248] / direction=RIGHT
[0249] / locus_tag="ITR"
[0250] / label="ITR"
[0251] / ApEinfo_label="ITR"
[0252] / ApEinfo_fwdcolor="#999999"
[0253] / ApEinfo_revcolor="#999999"
[0254] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0255] -0.5} {} 0} width 5 offset 0" rep_origin 1744..1971
[0256] / direction=RIGHT
[0257] / locus_tag="bGH"
[0258] / label="bGH"
[0259] / ApEinfo_label="bGH" / ApEinfo_fwdcolor="#999999"
[0260] / ApEinfo_revcolor="#999999"
[0261] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0262] -0.5} {} 0} width 5 offset 0" rep_origin 1983..2123
[0263] / direction=RIGHT
[0264] / locus_tag="ITR(l)"
[0265] / label="ITR(l)"
[0266] / ApEinfo_label="ITR"
[0267] / ApEinfo_fwdcolor="#999999"
[0268] / ApEinfo_revcolor="#999999"
[0269] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0270] -0.5} {} 0} width 5 offset 0" rep_origin 3040..3897
[0271] / direction=RIGHT
[0272] / locus_tag="Amp(R)"
[0273] / label="Amp(R)"
[0274] / ApEinfo_label="Amp(R)"
[0275] / ApEinfo_fwdcolor="#999999"
[0276] / ApEinfo_revcolor="#999999"
[0277] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0278] -0.5} {} 0} width 5 offset 0" rep_origin 4048..4715
[0279] / direction=RIGHT
[0280] / locus_tag="pUCori"
[0281] / label="pUCori"
[0282] / ApEinfo_label="pUCori"
[0283] / ApEinfo_fwdcolor="#999999"
[0284] / ApEinfo_revcolor="#999999"
[0285] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0286] -0.5} {} 0} width 5 offset 0" source 904..1008
[0287] / organism="recombinant plasmid"
[0288] / mol_type="other DNA"
[0289] / locus_tag="source:reco binant plasmid(l)"
[0290] / label="source:recombinant plasmid(l)"
[0291] / ApEinfo_label="source:recombinant plasmid"
[0292] / ApEinfo_fwdcolor="pink"
[0293] / ApEinfo_revcolor="pink"
[0294] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0295] -0.5} {} 0} width 5 offset 0" source 1642..4720
[0296] / organism="recombinant plasmid"
[0297] / mol_type="other DNA"
[0298] / locus_tag="source:recombinant plasmid(2)"
[0299] / label="source:recombinant plasmid(2)"
[0300] / ApEinfo_label="source:recombinant plasmid"
[0301] / ApEinfo_fwdcolor="pink"
[0302] / ApEinfo_revcolor="pink"
[0303] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0304] -0.5} {} 0} width 5 offset 0" misc_feature 1006..1641
[0305] / locus_tag="hGDNF"
[0306] / label="hGDNF"
[0307] / ApEinfo_label="hGDNF"
[0308] / ApEinfo_fwdcolor="#ff0000"
[0309] / ApEinfo_revcolor="green"
[0310] / ApEinfo_graphicformat="arrow_data {{00.50 1 200 -10
[0311] -0.5} {} 0} width 5 offset 0" misc_feature 159..903
[0312] / locus_tag="tMCK JNS"
[0313] / label="tMCK JNS" / ApEinfo_label="tMCK JNS"
[0314] / ApEinfo_fwdcolor="#ffffOO"
[0315] / ApEinfo_revcolor="green"
[0316] / ApEinfo_graphicformat="arrow_data {{0 0.5 0 1 2 0 0 -1 0 -0.5} {} 0} width 5 offset 0"
[0317] ORIGIN
[0318] 1 cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcaaag cccgggcgtc
[0319] 61 gggcgacctt tggtcgcccg gcctcagtga gcgagcgagc gcgcagagag ggagtggcca 1 1 actccatcac taggggttcc tgcggcctaa ggcaattgag atcggaattc gcccttaagc 181 tagccactac gggtctaggc tgcccatgta aggaggcaag gcctggggac acccgagatg 241 cctggttata attaacccca acacctgctg cccccccccc cccaacacct gctgcctgag 301 cctgagcggt taccccaccc cggtgcctgg gtcttaggct ctgtacacca tggaggagaa 361 gctcgctcta aaaataaccc tgtccctggt gggcccacta cgggtctagg ctgcccatgt 421 aaggaggcaa ggcctgggga cacccgagat gcctggttat aattaacccc aacacctgct 481 gccccccccc ccccaacacc tgctgcctga gcctgagcgg ttaccccacc ccggtgcctg 541 ggtcttaggc tctgtacacc atggaggaga agctcgctct aaaaataacc ctgtccctgg 601 tgggccacta cgggtctagg ctgcccatgt aaggaggcaa ggcctgggga cacccgagat 661 gcctggttat aattaacccc aacacctgct gccccccccc ccccaacacc tgctgcctga 721 gcctgagcgg ttaccccacc ccggtgcctg ggtcttaggc tctgtacacc atggaggaga 781 agctcgctct aaaaataacc ctgtccctgg tgggcccctc cctggggaca gcccctcctg 841 gctagtcaca ccctgtaggc tcctctatat aacccagggg cacaggggct gcccccgggt 901 cacgctagcc aaagcttctc gaggctggct agttaagcta tcaacaagtt tgtacaaaaa 961 agcaggcttt aaaggaacca attcagtcga cgctagctcg ccaccatgaa gttatgggat 1021 gtcgtggctg tctgcctggt gctgctccac accgcgtccg ccttcccgct gcccgccggt 1081 aagaggcctc ccgaggcgcc cgccgaagac cgctccctcg gccgccgccg cgcgcccttc 1141 gcgctgagca gtgactcaaa tatgccagag gattatcctg atcagttcga tgatgtcatg 1201 gattttattc aagccaccat taaaagactg aaaaggtcac cagataaaca aatggcagtg 1261 cttcctagaa gagagcggaa tcggcaggct gcagctgcca acccagagaa ttccagagga 1321 aaaggtcgga gaggccagag gggcaaaaac cggggttgtg tcttaactgc aatacattta 1381 aatgtcactg acttgggtct gggctatgaa accaaggagg aactgatttt taggtactgc
[0320] 1441 agcggctctt gcgatgcagc tgagacaacg tacgacaaaa tattgaaaaa cttatccaga 1501 aatagaaggc tggtgagtga caaagtaggg caggcatgtt gcagacccat cgcctttgat
[0321] 1561 gatgacctgt cgtttttaga tgataacctg gtttaccata ttctaagaaa gcattccgct
[0322] 1621 aaaaggtgtg gatgtatctg agtttatcgc ggccgcctcg agtctagacc cagctttctt
[0323] 1681 gtacaaagtg gttgatctag agggcccgta actagttgag cggccgcaac tcgagactct
[0324] 1741 agacgactgt gccttctagt tgccagccat ctgttgtttg cccctccccc gtgccttcct
[0325] 1801 tgaccctgga aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc
[0326] 1861 attgtctgag taggtgtcat tctattctgg ggggtggggt ggggcaggac agcaaggggg
[0327] 1921 aggattggga agacaatagc aggcatgctg gggatgcggt gggctctatg gccgcgggcc
[0328] 1981 gcaggaaccc ctagtgatgg agttggccac tccctctctg cgcgctcgct cgctcactga
[0329] 2041 ggccgggcga ccaaaggtcg cccgacgccc gggctttgcc cgggcggcct cagtgagcga
[0330] 2101 gcgagcgcgc agctgcctgc aggggcgcct gatgcggtat tttctcctta cgcatctgtg
[0331] 2161 cggtatttca caccgcatac gtcaaagcaa ccatagtacg cgccctgtag cggcgcatta
[0332] 2221 agcgcggcgg gtgtggtggt tacgcgcagc gtgaccgcta cacttgccag cgccctagcg
[0333] 2281 cccgctcctt tcgctttctt cccttccttt ctcgccacgt tcgccggctt tccccgtcaa
[0334] 2341 gctctaaatc gggggctccc tttagggttc cgatttagtg ctttacggca cctcgacccc
[0335] 2401 aaaaaacttg atttgggtga tggttcacgt agtgggccat cgccctgata gacggttttt
[0336] 2461 cgccctttga cgttggagtc cacgttcttt aatagtggac tcttgttcca aactggaaca
[0337] 2521 acactcaacc ctatctcggg ctattctttt gatttataag ggattttgcc gatttcggcc
[0338] 2581 tattggttaa aaaatgagct gatttaacaa aaatttaacg cgaattttaa caaaatatta
[0339] 2641 acgtttacaa ttttatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc
[0340] 2701 cagccccgac acccgccaac acccgctgac gcgccctgac gggcttgtct gctcccggca
[0341] 2761 tccgcttaca gacaagctgt gaccgtctcc gggagctgca tgtgtcagag gttttcaccg
[0342] 2821 tcatcaccga aacgcgcgag acgaaagggc ctcgtgatac gcctattttt ataggttaat
[0343] 2881 gtcatgataa taatggtttc ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga
[0344] 2941 acccctattt gtttattttt ctaaatacat tcaaatatgt atccgctcat gagacaataa
[0345] 3001 ccctgataaa tgcttcaata atattgaaaa aggaagagta tgagtattca acatttccgt
[0346] 3061 gtcgccctta ttcccttttt tgcggcattt tgccttcctg tttttgctca cccagaaacg
[0347] 3121 ctggtgaaag taaaagatgc tgaagatcag ttgggtgcac gagtgggtta catcgaactg
[0348] 3181 gatctcaaca gcggtaagat ccttgagagt tttcgccccg aagaacgttt tccaatgatg
[0349] 3241 agcactttta aagttctgct atgtggcgcg gtattatccc gtattgacgc cgggcaagag
[0350] 3301 caactcggtc gccgcataca ctattctcag aatgacttgg ttgagtactc accagtcaca 3361 gaaaagcatc ttacggatgg catgacagta agagaattat gcagtgctgc cataaccatg
[0351] 3421 agtgataaca ctgcggccaa cttacttctg acaacgatcg gaggaccgaa ggagctaacc
[0352] 3481 gcttttttgc acaacatggg ggatcatgta actcgccttg atcgttggga accggagctg
[0353] 3541 aatgaagcca taccaaacga cgagcgtgac accacgatgc ctgtagcaat ggcaacaacg
[0354] 3601 ttgcgcaaac tattaactgg cgaactactt actctagctt cccggcaaca attaatagac
[0355] 3661 tggatggagg cggataaagt tgcaggacca cttctgcgct cggcccttcc ggctggctgg
[0356] 3721 tttattgctg ataaatctgg agccggtgag cgtgggtctc gcggtatcat tgcagcactg
[0357] 3781 gggccagatg gtaagccctc ccgtatcgta gttatctaca cgacggggag tcaggcaact
[0358] 3841 atggatgaac gaaatagaca gatcgctgag ataggtgcct cactgattaa gcattggtaa
[0359] 3901 ctgtcagacc aagtttactc atatatactt tagattgatt taaaacttca tttttaattt
[0360] 3961 aaaaggatct aggtgaagat cctttttgat aatctcatga ccaaaatccc ttaacgtgag
[0361] 4021 ttttcgttcc actgagcgtc agaccccgta gaaaagatca aaggatcttc ttgagatcct
[0362] 4081 ttttttctgc gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc agcggtggtt
[0363] 4141 tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt cagcagagcg
[0364] 4201 cagataccaa atactgtcct tctagtgtag ccgtagttag gccaccactt caagaactct
[0365] 4261 gtagcaccgc ctacatacct cgctctgcta atcctgttac cagtggctgc tgccagtggc
[0366] 4321 gataagtcgt gtcttaccgg gttggactca agacgatagt taccggataa ggcgcagcgg
[0367] 4381 tcgggctgaa cggggggttc gtgcacacag cccagcttgg agcgaacgac ctacaccgaa
[0368] 4441 ctgagatacc tacagcgtga gctatgagaa agcgccacgc ttcccgaagg gagaaaggcg
[0369] 4501 gacaggtatc cggtaagcgg cagggtcgga acaggagagc gcacgaggga gcttccaggg
[0370] 4561 ggaaacgcct ggtatcttta tagtcctgtc gggtttcgcc acctctgact tgagcgtcga
[0371] 4621 tttttgtgat gctcgtcagg ggggcggagc ctatggaaaa acgccagcaa cgcggccttt
[0372] 4681 ttacggttcc tggccttttg ctggcctttt gctcacatgt
[0373] The above AAV vector may be equally used for the expression of BDNF, for example wherein the "hGDNF" sequence is substituted with a BDNF-encoding sequence, such as herein described.
[0374] The above AAV vector sequence may be modified with an alternative promoter sequence, such as tMCK. In particular, the MHCK7 promoter sequence may be substituted with an alternative promoter sequence, such as tMCK. The MHCK7 promoter sequence may be substituted with an alternative promoter sequence, such as tMCK and the "hGDNF" sequence may be substituted with a BDNF- encoding sequence, such as herein described.
Claims
CLAIMS1. A brain-derived neurotrophic factor (BDNF) and / or a glial cell line-derived neurotrophic factor (GDNF) for use in the treatment or prevention of Charcot-Marie-Tooth disease (CMT) or other hereditary peripheral neuropathies, in a subject, wherein the treatment comprises gene therapy to increase the expression of BDNF and / or GDNF in one or more muscle cells of the subject, or non- systemic injection of the BDNF and / or GDNF into one or more muscles of the subject.
2. The BDNF and / or GDNF for the use according to claim 1, wherein the BDNF and / or GDNF is encoded in a nucleic acid for expression, optionally wherein the nucleic acid is a viral vector.
3. The BDNF and / or GDNF for the use according to any preceding claim, wherein the expression of the BDNF and / or GDNF is controlled by a muscle-specific promoter.
4. The BDNF and / or GDNF for the use according to any preceding claim, wherein expression of the BDNF and / or GDNF is controlled by a muscle-specific promoter comprising or consisting of any of the promoters selected from CK6, MHCK7, dMCK, tMCK, CK8, CK8e, desmin, C5-12, alpha-actin, HSA, and HSA / CMV.
5. The BDNF and / or GDNF for the use according to any preceding claim, wherein expression of the BDNF and / or GDNF is controlled by a muscle-specific promoter comprising or consisting of the sequence of SEQ. ID NO: 1 or 2, or a functional variant thereof.
6. The BDNF and / or GDNF for the use according to any preceding claim, wherein the BDNF and / or GDNF is encoded in an adeno-associated virus (AAV) vector.
7. The BDNF and / or GDNF for the use according to any preceding claim, wherein the BDNF and / or GDNF is encoded in an adeno-associated virus (AAV) vector packaged in an AAVMYO or MyoAAV capsid.
8. The BDNF and / or GDNF for the use according to any preceding claim, wherein the treatment comprises administration of nucleic acid encoding BDNF and / or GDNF for expression, wherein the administration is systemic, or the administration is local administration to a nerve or muscle tissue.
9. The BDNF and / or GDNF for the use according to claim 1, wherein the treatment comprises local non-systemic injection of BDNF and / or GDNF protein into the subject, such as injection of BDNF and / or GDNF into a muscle in the subject.
10. The BDNF and / or GDNF for the use according to any preceding claim, wherein the BDNF comprises or consists of the sequence of SEQ ID NO: 4 or 5, or a functional variant thereof; and / or wherein the GDNF may comprises or consists of the sequence of SEQ. ID NO: 9 or 10, or a functional variant thereof.
11. The BDNF and / or GDNF for the use according to any preceding claim, wherein the CMT is an ARS- related CMT.
12. The BDNF and / or GDNF for the use according to any preceding claim, wherein the CMT disease is the CMT2D subtype or DI-CMTC subtype.
13. The BDNF and / or GDNF for the use according to any preceding claim, wherein the use is in combination with one or more other therapeutically active agents, such as growth factors.
14. The BDNF and / or GDNF for the use according to any preceding claim, wherein the use is in combination with NT-3 and / or VEGFiss therapy.
15. A nucleic acid encoding BDNF and / or GDNF and a muscle-specific promoter, which controls the expression of the BDNF and / or GDNF.
16. The nucleic acid according to claim 15, wherein the muscle-specific promoter comprises or consists of any of the promoters selected from CK6, MHCK7, dMCK, tMCK, CK8, CK8e, desmin, C5-12, alphaactin, HSA, and HSA / CMV.
17. The nucleic acid according to claim 15 or 16, wherein the nucleic acid is a viral vector, optionally an AAV vector.
18. The nucleic acid according to claim 15 or 16, wherein the nucleic acid further encodes one or more growth factors.
19. A virus particle, or virus like-particle (VLP), comprising the nucleic acid according to any one of claims 15-18.
20. A composition comprising the nucleic acid of any of claim 15-18, or the viral particle or VLP according to claim 19, and a carrier.
21. The composition according to claim 20, wherein the composition further comprises nucleic acid encoding one or more growth factors.
22. A composition comprising: a) recombinant BDNF and / or GDNF; b) one or more growth factors or nucleic acid encoding one or more growth factors; and c) a pharmaceutically acceptable carrier.
23. A method of manufacturing the nucleic acid according any of claims 15-18, the method comprising the insertion of a muscle-specific promoter sequence into a nucleic acid with a sequence encoding BDNF and / or GDNF, such that the muscle-specific promoter is arranged to control the expression of the BDNF and / or GDNF.
24. A method of treatment or prophylaxis of a subject for Charcot-Marie-Tooth disease (CMT), wherein the treatment or prophylaxis comprises:- the administration of BDNF and / or GDNF to one or more muscles of the subject; and / or- the administration of nucleic acid to increase the expression of BDNF and / or GDNF in one or more muscle cells of the subject.
25. The nucleic acid according to any of claims 15-18, the viral particle or VLP according to claim 19, or the composition according to any of claims 20-22, for use in the treatment or prevention of CMT.
26. A kit comprising the nucleic acid according to any of claims 15-18, the viral particle or VLP according to claim 19, or the composition according to any of claims 20-22, and optionally one or more syringes.
Citation Information
Patent Citations
Methods of treatment of motor neuron diseases using members of the BDNF / NT-3 / NGF family of molecules
EP0593516B1
Method of enhancing the delivery of growth factors
EP0938333B1
AAV vectors with myelin protein zero promoter and uses thereof for treating schwann cell-associated diseases like charcot-marie-tooth disease
US20220323611A1
T-cell therapy to neurodegenerative diseases
WO2012066495A2
Genetically modified muscle cells which express neurotrophic factors
WO2012117373A1
